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The field of immunoengineering is highly interdisciplinary, involving the insights from 
various other fields of studies such as physiology, computation, pharmacology, materials science 
and many more. With the recent progress in technology development, analyzing detailed cellular 
interactions that constitute the immune system has become possible, and many more biological 
and engineering tools became within reach for precise investigation and modulation of immune 
responses. As a result, many breakthroughs have been achieved in various clinical settings. 
Immunotherapies, such as anti-PD-1 antibody and chimeric antigen receptor T cells, 
revolutionized cancer immunotherapy, while genome sequencing and nanotechnology allowed for 
the rapid development of various vaccines in response to the recent outbreak of Coronavirus 
Disease 2019. Also, analysis of massive amount of data collected from the bacterial genome within 
various parts of the body, called the microbiome, is enabling us to study the relationship between 
the microbiota and human body and health, and is suggesting new ways of treating once thought 
to be hard-to-treat diseases. 
In Chapters II and III, strategies for modulating the immune responses using biomaterials 
for cancer immunotherapy are introduced. Chapter II describes silica-based nanoparticle-mediated 
stimulator of interferon gene (STING) agonist delivery. Compared to soluble form of STING 
agonist, it induced ~4-fold higher dendritic cell activation in vitro, accompanied by significantly 
enhanced cytokine secretion, which together with prolonged immune cell activation within the 
tumor microenvironment, greatly improved therapeutic efficacy of the STING agonist in mouse 
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melanoma models. In Chapter III, an adjuvant and a model neoantigen peptide were formulated 
into a nanoparticle, which increased dendritic cell activation and antigen presentation by 2~4 folds 
and 4-folds, respectively in vitro compared to soluble formulation. It translated to ~3 folds higher 
antigen-specific CD8+ T cell frequency in blood circulation in mice. In addition, an attempt to 
induce a stronger chemokine gradient to recruit more T cells to tumor from the blood circulation 
was also investigated. 
In Chapter IV, use of lipid-based nanoparticle to formulate vaccines against infectious 
diseases, including human immunodeficiency virus-1 (HIV-1) and severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2), is introduced. The aim of the study was to load subunit 
proteins into lipid-based nanoparticles while maintaining the structural intactness and to induce 
enhanced antibody responses when vaccinated to animals. Nanoparticle vaccine enhanced in vitro 
dendritic cell activation and antigen presentation, while improving antigen trafficking to lymph 
node in vivo, leading to significantly enhanced IgG responses in animals. 
In Chapter V, I investigated the effects of prebiotics on gut microbiota and immune 
responses during cancer immunotherapy using a cancer vaccine. Recently the communication 
between the gut microbiota and the immune system started to be revealed, thanks to mass data 
analysis and genome sequencing becoming more available for general research purposes. Also, 
studies are reporting the correlation of certain bacterial species and their metabolites with 
immunotherapeutic outcomes during cancer immunotherapies. Here, I sought to investigate the 
effects of prebiotics consumption on gut microbiota and if changes in bacterial frequencies can 
modulate the immune responses following cancer vaccination using mouse tumor models. 
Lastly in Chapter VI, I present the overall review of the studies in this thesis. Also, future 
directions to pursue are discussed with ways to provide complementing information to some of the 
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experiments, which currently can only suggest limited insights, and potential clinical translation 
in mind.
 1 
CHAPTER I. Introduction 
 
1.1. Background 
Immunotherapy has gathered huge interests especially in the recent decades with the advent 
of advanced biological tools and computation technologies. With accumulating knowledge and 
data, immunoengineering approach to treat diseases became very effective and practical over the 
years, creating many different strategies of modulating the immune responses depending on the 
type of diseases. Here, strategies for treating cancer and infectious diseases by modulating innate 
and adaptive immune responses using immune-modulating agents and biomaterials as tools will 
be discussed. Depending on the type of disease, different stages of immune responses were 
targeted for modulation with strategies and materials carefully chosen. Described in more details 
in the following pages, the main research areas to be discussed are (1) cancer immunotherapy, (2) 
development of vaccines for infectious diseases, and (3) prebiotics delivery for enhancing immune 
responses. 
 
1.2. Cancer immunotherapy 
One of the most actively investigated areas of immunoengineering research is cancer 
immunotherapy. Programmed cell death receptor-1 (PD-1) blockade therapy may be one of the 
most well-known recent breakthrough discoveries in the field of cancer immunotherapy (1, 2). 
Within the tumor microenvironment, immunosuppression becomes more severe as the tumor 
progresses to later stages, through various mechanisms (3, 4). One of the major pathways the 
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spontaneously formed tumor-specific CD8+ T cells are inhibited is by the engagement of their PD-
1 receptors with the ligands, PD-L1 and PD-L2, expressed on tumor cells. Treatment of anti-PD-
1 or anti-PD-L1 antibodies has proven to have significantly meaningful efficacies in various 
cancers, including melanoma, colon carcinoma, head and neck squamous cell carcinoma, and 
many more (5-10). Another breakthrough is now a well-known chimeric antigen receptor T cell 
therapy (11-14). So called CAR-T, falls into the category of adoptive cell transfer (ACT) therapy, 
which is one of the cancer therapeutic techniques that transfers ex vivo expanded T cells to patients 
from different sources including autologous tumor infiltrating T cells and genetically modified 
peripheral T cells (14). Usually, the patient receiving ACT is preconditioned by eliminating pre-
existing lymphocytes in the body to maximize availability of cytokines to the transferred T cells 
that leads to greater expansion post transfer and prolong their existence in the blood circulation. 
CAR-T targeting CD19 expressed by leukemic B cells achieved outstanding response rates in 
patients with acute lymphoblastic leukemia (ALL) and have attracted a tremendous number of 
resources to the field. With CAR-Ts that target different receptors than CD19, such as CD20 and 
CD22, this technology is continuously evolving to prevent relapse and be more effective in treating 
different kinds of Hematologic Malignancies (15, 16). 
Together with the aforementioned hypes in the field, the discovery of neoantigen brought 
a huge revolution to how we perceive cancer which was once thought to be a disease that is expert 
at eluding the immune surveillance (17). Recent advances in genomics and proteomics discovered 
mutations within the somatic genes of tumor cells. The so-called tumour mutanome revealed that 
every tumor has a unique set of driver and passenger mutations (17-19). Tumor cells expressing 
mutated proteins (neoantigens) present these new epitopes in the context of major 
histocompatibility complex (MHC) molecules. In contrast to tumor associated antigens (TAA), 
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whose expression is shared among healthy and tumor cells, neoantigens arise from mutations in 
tumors and are, therefore, fully restricted to tumor cells. Thus, immunotherapies that capitalize on 
rich genomic and proteomic bioinformatics data for personalized strategies directed to neoantigens 
are enabling highly specific targeting of tumour cells without risking healthy tissues or being 
limited by immune tolerance (20). Using the neoantigens of different kinds that are synthesized 
into forms of DNA, RNA or peptides, cancer vaccines were produced to effectively treat different 
kinds of cancers, and currently many clinical trials are undergoing either as a monotherapy or in 
combination with various delivery vehicles and adjuvants (21-24). 
Despite these advances, still only a fraction of patients undergo complete tumor regression. 
There are many reasons for this, including immunosuppressive TME and suboptimal immune 
activation by therapeutic treatments. Immune response during cancer therapy is initiated by the 
release of tumor-specific antigens from spontaneously dying tumor cells or drug- or immune cell-
induced tumor cell death. These antigens are taken up by antigen presenting cells, processed into 
peptides that are presented on the MHC molecules, which together with co-stimulatory ligands on 
the APCs (B7.1/2) activate naïve T cells in the lymph nodes. T cells then proliferate and become 
effector cells, which effuse out from the lymph node into the blood circulation. They migrate 
following the chemokine gradient, traffic to and infiltrate the tumor. Many immunoengineering 
approaches are developed to solve the aforementioned issues that cause suboptimal therapeutic 
outcomes, by taking various strategies to modulate different stages of the immune responses and 
immune cell types, such as dendritic cells and T cells. 
Use of nanoparticles is one of the most commonly used strategies to enhance the efficacies 
of various therapeutics (25). Depending on the material and structural design of the nanoparticle, 
nanoparticle-mediated drug or vaccine delivery is reported to improve pharmacokinetics after 
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systemic administration, enabling co-delivery of adjuvant to antigen presenting cells (APC) for 
enhanced innate immune responses and increase the delivery of drugs to a targeted site within the 
body (26, 27). 
Another hurdle to achieving successful cancer immunotherapy is to increase tumor-
infiltration of antigen-specific CD8+ T cells. Many types of tumors are reported to down-regulate 
the expression of T cell attractant chemokines or have immature blood vessels, so-called leaky 
vasculature that limits the transmigration of T cells across the blood vessels into tumor tissues (28-
30). In such cases, the CD8+ T cells in the blood circulation either generated by vaccination or by 
adoptive cell transfer, fail to traffic to and infiltrate tumor. It is reported that the degree of tumor-
infiltration by lymphocytes is correlated with the patient prognosis (31, 32), highlighting the 
importance of finding the means to overcome this issue. In some studies, treatment of chemo-drugs, 
such as cisplatin and temozolomide (33), or agonists of pattern recognition receptors (PRR), such 
as stimulator of interferon genes (STING) agonist and cytosine-guanine-rich (CpG) motifs (CpG-
ODN) (34, 35), within tumors triggered the release of lymphocyte attractant chemokines from the 
tumor, increasing the tumor infiltration by T cells and NK cells. Therefore, it is presumed that in 
addition to other forms of immunotherapies that stimulate inflammatory immune responses against 
tumor, combinatorial treatment of therapeutics to recruit lymphocytes to tumor may provide a great 
synergy to achieving improved therapeutic outcome. 
In Chapters II and III, immunomodulation strategies using nanoparticle-mediated drug and 
vaccine delivery for cancer immunotherapy are discussed. First, a silica-based nanoparticle was 
used to deliver a model STING agonist to enhance the activation of dendritic cells (DC), which 
led to improved tumor growth suppression in mouse melanoma models. Next, a charge-induced 
nano-sized complex of cationic polymer and CpG was used to formulate a peptide-based cancer 
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vaccine to induce stronger DC activation and antigen presentation and subsequent CD8+ T cell 
responses. In combination with the vaccine treatment, STING agonist was treated to tumor to 
induce T cell attractant chemokine release from the tumor, which resulted in increased tumor 
infiltration by the vaccine-induced CD8+ T cells in the blood circulation. 
 
1.3. Infectious diseases 
Pathogenic bacteria and virus cause infectious diseases, the symptoms of which range from 
light to heavy illnesses, in some cases that reach serious morbidity or mortality. Many have been 
identified in history and are now well-known and thoroughly studied, while there are still newly 
emerging diseases that sometimes are alerting to the human society. Historically, there had been a 
number of outbreaks of infectious diseases that were highly contagious, causing epidemics that 
sometimes led to pandemics (36-38). Plague by a species of bacteria that caused Black Death and 
avian-origin viral infections that caused Spanish Flu are among many well-known pandemics that 
took many lives. With improved sanitization and more importantly by the advent of chemo-drugs 
and vaccines, many once thought to be detrimental and contagious diseases were able to be 
controlled and contained before being widely spread. 
While, on the bright side, many diseases are now in control with some of them even 
assumed to be extinct by ever improving vaccine and drug development technologies, there is a 
rising concern over the fight against infectious diseases. That is, the term between appearances of 
new pathogens with high transmissibility or mortality, thus with the potential to cause epidemic or 
to pandemic, is becoming shorter in the recent decades. One of the main reasons for the increased 
frequency is the apparent changes that have occurred in our society, such as overpopulation, 
increasing international travels and indoor activities. Most recently, first reported in December 
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2019, a novel corona virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) that spread throughout the world with an upsetting speed was declared a pandemic in March 
2020 and was named Coronavirus Disease 2019 (COVID-19). Unlike in the cases of similar 
viruses such as SARS-CoV that caused the 2002 epidemic and MERS-CoV that attracted global 
concerns due to its high mortality rate in 2012, both of which were managed to be contained, many 
conditions, such as ever-increasing international travels, overpopulation and mild- or 
asymptomatic, yet transmissible incubation period,  were met in the case of SARS-CoV-2 that let 
the virus exude out from the efforts to contain it regionally from where it began, and eventually 
spread globally at an epic speed to cause the pandemic (39). 
We have learned now that similar outbreaks will inevitably occur in future with shorter 
frequencies, which prompted global interest in developing interventions to counter diseases that 
cause such outbreaks. Broadly, those interventions can be categorized as either therapeutic or 
prophylactic. Both types of interventions ultimately aim to have a certain percentage of people in 
a community to have immunity that prevents further spread of the disease, which is termed 
communal/herd immunity. However, finding or discovering a therapeutic that shows sufficient 
efficacy each time an outbreak occurs, if at all possible, would be very challenging. Especially in 
the urgent setting of an epidemic outbreak, the extremely low percentile of drug candidates 
reaching the market and the typical time of 10 years spent for development of a new drug may 
seem even more unrealistic. To expedite the provision of efficacious drugs to the clinic, searching 
among drugs that are mostly FDA approved, called drug repurposing, is gaining a lot of attentions 
(40). However, when a novel pathogen arises, lack of preclinical study models and limited 
availability of pathogen and its biological/pathological information would still pose hurdles.  
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Similarly, vaccine development may also be challenging and time consuming when facing 
an epidemic outbreak by a novel pathogen. The process of developing a vaccine consists of two 
key steps: 1) identifying an antigen and 2) developing a delivery approach for said antigen to 
achieve robust cellular and humoral immunity. In case of COVID-19, our experiences of SARS-
CoV and MERS-CoV have enabled fast reaction against SARS-CoV-2 since analysis of viral 
genomic sequence and protein structures of ligands that bind to human receptors became rapidly 
available due to similarities between these viruses. It was discovered that SARS-CoV-2 can be 
targeted at specific sites of its surface glycoprotein called spike protein. 3D structural analyses 
have confirmed that the S1 subunit protein and more specifically the receptor binding domain 
(RBD) within the protein to be critical structural regions for the virus to bind with angiotensin-
converting enzyme 2 (ACE2) expressed on human cells and initiate infection (41, 42). Likewise, 
for future pathogens that may arise in future, various simulation and computation methods together 
with our experiences of encounters with previous variants of the pathogen may provide an 
expedited identification of targetable antigen. 
On the other hand, development of delivery approaches for efficient immune activation by 
a vaccine antigen is in the realm where we can invest on before an outbreak occurs (43, 44). 
Different types of vaccine technologies are used to develop vaccines which can be categorized 
depending on the type of antigen used: inactivated/attenuated virus, RNA, DNA and protein (45). 
Whole virus has been a type of vaccine conventionally used that brought a huge health benefit to 
human life, saving many lives while greatly reducing the cases of many major diseases, such as 
smallpox, tuberculosis and yellow fever. Live attenuated virus and inactivated virus are the two 
major types of whole virus vaccine. Live attenuated viruses are developed by passaging a virus 
multiple times in environments that differ from those of human hosts, making the virus lose its 
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ability to infect and replicate within human. In contrast, inactivated viruses are made by various 
ways to kill the virus, such as heating or chemical treatments. Therefore, as opposed to live 
attenuated vaccines, inactivated vaccines do not bear the risk of viral reversion. However, the 
reagents used to inactivate the live viruses often are damaging to the parts of the virion structure 
that is essential to the immunogenicity of the vaccine. Therefore, the vaccines synthesized with 
this method often fail to meet acceptable potency or need multiple vaccination regimen to achieve 
sufficient protection. 
In contrast to whole virus vaccines that are administered in the forms of virions, DNA, 
RNA and protein vaccines have an option to be encapsulated in delivery platforms which may 
enhance the vaccine potency. Many of the DNA and RNA vaccines (especially the RNA vaccines) 
currently under development for COVID-19 are in the forms of nanoparticles consisted of lipid-
based materials (46). Nanoparticles are used to achieve efficient trafficking of the vaccine antigen 
to the lymph node, co-delivery of adjuvant that further enhances the immune activation, and 
protection of antigen from degradation, benefiting the pharmacokinetics. 
It is important, however, to carefully design the structure and material of the delivery 
carrier depending on the type of antigen material, whether it being DNA, RNA or protein, the route 
of administration and expected pharmacokinetics after administration. Especially when protein 
subunits are used as the vaccine antigen, maintaining the quaternary and tertiary structures of the 
protein during the nanoparticle loading process is critical during the vaccine formulation, since it 
enables the vaccine to present appropriate epitopes to the immune cells, which is closely related 
to the generation of quality neutralizing antibodies that are effective at neutralizing the pathogens 
(47). In Chapter IV, generation of protein-based vaccines made in a form of lipid nanoparticle is 
introduced. Glycoproteins of human immunodeficiency virus-1 and RBD of SARS-CoV-2 are 
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used as model antigens to be loaded in the lipid nanoparticles, and rationale and the methods of 
formulating effective vaccines that generate potent antibody responses in mouse and rabbit are 
discussed. 
 
1.4. Effects of prebiotics on gut microbiome and immune responses 
 Microbiota is a collection of microorganisms that include bacteria, virus and fungi. 
Microbiome refers to the genomic materials as well as the physical entities of the microbes 
consisting the microbiota. It has been revealed that human body harbors multiple microbiotas 
depending on the organs or parts of the body. With the advances in sequencing tools and mass data 
analysis, people are able to take a deeper look into the composition of each microbiota and the 
factors that influence the bacterial residents within the microbiota. 
 The gut microbiome is one of the most actively studied subjects of microbiome research, 
where the food that we consume has been identified to be a critical factor to how gut bacteria react 
and metabolize, and ultimately to our general health (48, 49). More importantly, recent studies are 
finding scientific bases for the close relationship between the gut microbiota and host immunity. 
Depending on how the diet is regulated, one may either suffer from autoimmune or inflammatory 
disorders or may elicit robust immune responses against intrusions of external pathogens (50-52). 
In particular, consumption of dietary fibers is known to provide sources for gut bacteria to 
metabolize on, which upon fermentation generates short chain fatty acids (SCFA) as the metabolic 
products. Studies are reporting the effects of SCFA on the various types of immune cells, including 
dendritic cells, T cells, and many more (53-55), and their contributions during cancer 
immunotherapy (56-58). Although there are contrasting reports of the effect of SCFA levels in 
blood on the clinical responses upon therapeutic interventions, such as anti-PD-1 or anti-CTLA-4 
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antibody treatments (58, 59), it is certain that the bacterial metabolites have significant impact on 
how the immune system is regulated. 
 Based on these clues, people were able to predict the relationship between the gut 
microbiome and the way hosts respond to vaccination. From mice studies, immune responses 
induced by vaccination were varied based on whether a mouse received antibiotics or was kept in 
a germ-free environment (60, 61). Later, similar effects were observed in human cases, where 
antibiotic treatment led to marked reduction in bacterial loads in the gut and significantly reduced 
flu vaccine efficacy (62, 63). Therefore, from an immunoengineering perspective, modulation of 
immune response upon vaccination may be achieved by influencing the gut microbiome, and 
consumption of dietary fibers is a great way to achieve that goal. In Chapter V, the effects of 
prebiotics consumption on microbiome and subsequent influence on cancer vaccine efficacy in 
mouse tumor model are discussed. 
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CHAPTER II. Improving STING Agonist Delivery for Cancer Immunotherapy Using 
Biodegradable Mesoporous Silica Nanoparticles 
 
2.1. Abstract 
Stimulator of interferon genes (STING) activation by intratumoral STING agonist treatment has 
been recently shown to eradicate tumors in preclinical models of cancer immunotherapy, 
generating intense research interest and leading to multiple clinical trials. However, there are many 
challenges associated with STING agonist-based cancer immunotherapy, including low cellular 
uptake of STING agonists. Here, biodegradable mesoporous silica nanoparticles (bMSN) with an 
average size of 80 nm have been developed for efficient cellular delivery of STING agonists. 
STING agonists delivered via bMSN potently activate innate and adaptive immune cells, leading 
to strong anti-tumor efficacy and prolonged animal survival in murine models of melanoma. 
Delivery of immunotherapeutic agents via biodegradable bMSN is a promising approach for 
improving cancer immunotherapy. 
 
2.2. Introduction 
Exogenous nucleic acids that have successfully bypassed external sensing and appear in 
the cytosol are processed by cyclic GMP–AMP synthase (cGAS) into cyclic dinucleotides (CDNs), 
which engage stimulator of interferon genes (STING) molecules positioned along the endoplasmic 
reticulum. This triggers the interferon regulatory factor 3 (IRF-3) and nuclear factor kappa-light-
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chain-enhancer of activated B cells (NFB) signaling pathways and leads to type I interferon and 
pro-inflammatory cytokine production. In addition to protection against viral and bacterial 
infections, recent findings have also revealed a critical role of STING in initiating immune 
responses against cancer. Numerous studies have reported promising anti-cancer effects of STING 
agonists (64, 65). Importantly, STING agonist treatment induces significant anti-tumor immune 
responses, leading to complete tumor regression and durable anti-tumor immunity in multiple 
murine tumor models (66, 67). Compared with other PRR-binding adjuvants, STING agonists 
showed a distinct potency in that their sole treatment led to complete regression of established 
tumors in preclinical settings. The role of STING agonists in triggering type I interferon response 
leading to activation of various immune cell types suggests many potential applications for cancer 
treatment. Based on many promising preclinical studies, two types of STING agonist have 
undergone clinical evaluation as a single treatment or in combination with immune checkpoint 
blockers. Thus, STING has sparked intense research interest in the field of cancer immunotherapy 
(68, 69), and there are multiple clinical trials underway to evaluate the therapeutic efficacy of 
STING agonists. 
Despite their outstanding efficacies against various types of tumors, there are several 
hurdles of using soluble forms of STING agonist that limits their clinical translation. As STING 
agonists are based on cyclic dinucleotides with negative charges, their cellular permeability is 
minimal. Since STING molecules reside within the cytosol where endoplasmic reticulum is located, 
inability to permeate into cytosol leads to suboptimal activation of STING at a given dose. Also, 
due to their small molecular weight, STING agonists diffuse rapidly into systemic circulation upon 
injection, which may potentially cause severe off-target side-effects. Therefore, most preclinical 
and clinical studies with STING agonists have been limited to direct intratumoral injection, which 
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limits their use to treating local tumors. A recent report on STING activation in T cells leading to 
cell death exposes a negative effect of STING activation on cell types other than innate immune 
cells (70). In addition, since natural STING agonists are based on inherently unstable CDN 
structures, they exhibit a fast clearance from blood circulation. Lastly, the amount of STING 
agonist injected to tumor has been shown to dictate CD8+ T cell response (71), underscoring the 
importance of regulating the dose and pharmacokinetics of STING agonist to achieve robust anti-
tumor immunity. 
Here, we sought to promote cellular delivery of STING agonists using a well-established 
nanoparticle system with a strong track record of biocompatibility, safety, and manufacturability, 
considering the overarching direction of design to clinical translation. In particular, mesoporous 
silica nanoparticle (MSN) is a widely used inorganic drug delivery nanocarrier with tunable size, 
low immunogenicity, controlled release of cargo materials, and facile and low-cost preparation 
process (72, 73). However, while synthetic MSNs composed of amorphous silica are generally 
considered to be biocompatible, their limitations include relatively small pore sizes for drug 
loading, slow biodegradation, and long-term tissue retention (74-78). To address these issues, we 
have developed biodegradable mesoporous silica nanoparticles (bMSN) for cytosolic delivery of 
STING agonists. We have recently shown that bMSN with a less-dense Si-O-Si matrix undergoes 
faster biodegradation process than conventional MSN and that bMSN’s large pore size ranging 5-
10 nm allows for efficient loading and delivery of biomacromolecules for combination cancer 
treatments (79). Here, we report that bMSN surface-modified with amine serves as a promising 
platform for cellular delivery of STING agonists and immune activation. Using two murine models 
of melanoma, we demonstrate the therapeutic efficacy of bMSN carrying STING agonists, 
highlighting the potential of bMSN for applications in cancer immunotherapy. 
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2.3. Materials and Methods 
Synthesis of bMSN and CDA loading 
We synthesized bMSN by an oil-water biphase reaction approach.[22,41] Twenty-four ml 
of (25 wt %) CTAC solution and 0.18 g of TEA were added to 36 ml of water and stirred gently 
at 60 °C for 1 hr. Twenty ml of TEOS in cyclohexane (10 v/v %) was carefully added to 60 mL of 
the water-CTAC-TEA solution (0.3 M CTAC and 20 mM TEA) and kept at 60 °C. The reaction 
was kept at a constant temperature with continuous stirring for 18 hr to obtain nanoparticles. They 
were washed with ethanol for 3 times and water for 2 times with centrifugation at 15,500g for 15 
min. Surfactant was removed by incubating the nanoparticles in 10% NH4NO3/ethanol (v/v) at 
50 °C overnight, followed by washing. The resulting nanoparticles were freeze-dried and stored at 
4°C until use. To load CDA, 40 µg of CDA was mixed with 225 µg of bMSN in 5 mM histidine 
buffer, followed by 1 min of bath sonication. The mixture was incubated in 37 °C for 1 hour under 
constant shaking, then centrifuged at 10,000 g for 5 min. After removing the supernatant, the pellet 
was dispersed into PBS. The resulting CDA@bMSN showed 96.3% of CDA loading efficiency. 
In vivo studies 
Animals were cared for following the federal, state, and local guidelines. The University 
of Michigan, Ann Arbor is an AAALAC international accredited institution, and all work 
conducted on animals was in accordance with and approved by the Institutional Animal Care and 
Use Committee (IACUC) with the protocol # PRO00008587. Female C57BL/6 mice, 5-6 weeks 
in age (The Jackson Laboratory) were inoculated subcutaneously with 3x105 mouse melanoma 
cells (either B16F10 or B16F10OVA) on the right-side flank. After 6 days, mice received CDA 
formulations (PBS as control) via intratumoral injection. Blood sampling and tumor excision were 
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performed on the indicated time points. Blood samples were collected from the facial vein using a 
lancet. In a separate study, tumor sizes were measured every 2-3 days for monitoring tumor growth. 
Statistical analysis 
Data are presented as mean ± SEM. Data were approximately normally distributed, and 
variance was similar between the groups. Experiments were repeated multiple times as 
independent experiments with the sample size indicated in the figure captions. Data were analyzed 
using either one-way analysis of variance (ANOVA) or two-way ANOVA, followed by Tukey’s 
multiple comparison test for comparison of multiple groups using Prism 7.0e (GraphPad Software). 
Animal survival was analyzed by the log-rank (Mantel−Cox) test. *p < 0.05, **p < 0.01, ***p < 
0.001, and ****p < 0.0001. 
 
2.4. Results and Discussion 
We synthesized bMSN as we previously reported with some modifications for cytosolic 
delivery of STING agonists (79). The resulting bMSN had an approximate average diameter of 80 
nm, as visualized by transmission electron microscopy (TEM) (Figure 2-1a). Compared with 
conventional mesoporous silica nanoparticles, bMSN had a larger pore size (5 – 10 nm) and a 
thinner Si-O-Si matrix that allowed for rapid degradation within 120 hours in a physiological 
condition (Figure 2-1b). We loaded bMSN with a model STING agonist, bis-(3'-5')-cyclic dimeric 
adenosine monophosphate (CDA). Since CDA is a dicyclic nucleotide with anionic charges, the 
silica surface of bMSN was modified with amines (-NH2) to facilitate charge-mediated drug 
loading. The amine-modification changed the zeta potential of bMSN from -27.6 mV to 9.3 mV 
but did not affect the size of the nanoparticles (Figure 2-1c,d). The resulting bMSN-NH2 
(henceforth referred to as bMSN) was incubated at various concentrations with a fixed amount of 
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CDA (8 µg). After CDA was simply mixed and incubated with pre-formed bMSN for 1 hr, we 
observed > 90% loading of 8 µg CDA into 25 µg of bMSN (Figure 2-1e), indicating drug loading 
of ~290 µg per mg of bMSN (CDA@bMSN). CDA was released from CDA@bMSN within 1 hr 
at pH 7.0 (Figure 2-1f). However, when incubated at a slightly acidic condition of pH 6.0 
mimicking the conditions within the tumor microenvironment (TME) (80), we observed slower 
release of CDA (Figure 2-1f). 
 
Figure 2-1 Cellular delivery of STING agonists using bMSN. (a) TEM image of bMSN. (b) Degradation of bMSN in a 
physiological condition (Krebs-Henseleit solution at 37 °C). (c) Surface charge and (d) hydrodynamic size of bMSN measured 
before and after amine-modification using DLS. Particles were transferred to water for measurements. (e)  CDA-loading capacity 
of bMSN. (f) CDA Release profiles in different pH conditions. All data are presented as mean ± SEM, showing representative 
results from two independent studies with n = 3, with the exception of (e) with n = 1. Scale bars in (a) and (b) = 100 nm. 
 
Next, we examined cellular uptake of CDA@bMSN using mouse bone marrow-derived 
dendritic cells (BMDCs), as a widely used surrogate for APCs. BMDCs incubated with free 
fluorophore-tagged CDA for 6 hr showed a minimal increase in the fluorescence signal (Figure 2-
2a), whereas BMDCs incubated with CDA@bMSN exhibited markedly enhanced CDA signal 
 17 
(Figure 2-2a). Similarly, confocal microscopy revealed that BMDCs and B16F10 melanoma cells 
incubated with fluorophore-tagged CDA@bMSN exhibited much stronger cytosolic fluorescence 
signal, compared with minimal signal in cells treated with free CDA (Figure 2-2b, Figure 2-2c), 
demonstrating efficient bMSN-mediated cytosolic delivery of STING agonist. 
In addition, CDA@bMSN treatment led to robust BMDC activation, as evidenced by 
significantly increased expression of CD40 (P < 0.0001) and CD86 (P < 0.001), compared with 
free CDA treatment (Figure 2-2d), likely due to the increased cellular uptake of CDA@bMSN. 
Blank bMSN slightly increased the expression level of CD40, but not CD86, indicating minimal 
immune activation by the blank bMSN itself. Next, we used THP1-Blue ISG (human monocyte-
derived cells expressing a reporter gene for STING activation) to study the effects of CDA@bMSN 
on STING activation. Compared with free CDA, CDA@bMSN induced significantly stronger 
STING activation even at 12.5 µg/ml dose of CDA (P < 0.0001, Figure 2-2e), indicating 
amplification STING activation by bMSN-mediated delivery of CDA. Notably, both THP1-Blue 
ISG cells and primary CD8+ T cells incubated with either free CDA or CDA@bMSN exhibited 
similar levels of viability (Figure 2-2f, Figure 2-2g), showing biocompatibility of CDA@bMSN. 
We have also previously reported biological safety of the bMSN platform (79). Taken together, 
compared with free soluble CDA, CDA@bMSN significantly improved cellular uptake of CDA 
and amplified STING activation, without negatively affecting cytotoxicity. 
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Figure 2-2. Effects of bMSN-mediated CDA delivery in vitro. (a-c) Uptake of CDA by BMDCs assessed in vitro with (a) flow 
cytometry and (b,c) confocal microscopy. (d) Activation of BMDCs measured by flow cytometry after 4 hr of incubation. (e) 
STING activation of human monocyte-derived THP1-Blue ISG cells measured after overnight incubation. Relative viability of 
THP1-Blue ISG cells (f) and CD8+ T cells (g) after STING agonist treatment, measured using cell counting kit-8. All data are 
presented as mean ± SEM, showing representative results from two independent studies with n = 3, Scale bars in (b,c) = 5 µm. **p 
< 0.01, ***p < 0.001, ****p < 0.0001 analyzed by one-way or two-way ANOVA with Tukey’s HSD multiple comparison post hoc 
test. 
 
We examined secretion of cytokines and chemokines from BMDCs treated with CDA 
formulations. In line with the enhanced uptake of CDA and activation of BMDCs (Figure 2-2a-
d), CDA@bMSN treatment significantly increased the release of IL-6, IL-12p40, IFN-β, CXCL10, 
CCL2, CCL3, and CCL5 from BMDCs, compared with free CDA (P < 0.0001, Figure 2-3a). 
Although tumor-infiltrating immune cells are known as the major cell types that are activated by 
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STING agonists and initiate anti-tumor immune response, tumor cells also have been shown to 
respond to STING agonists (81, 82). We examined whether CDA treatment can promote cytokine 
and chemokine production from melanoma cell lines, B16F10 and B16F10OVA. Tumor cells 
incubated with free CDA did not release any detectable levels of cytokines or chemokines; 
however, CDA@bMSN treatment led to significantly amplified secretion of CXCL10 and CCL5 
from B16F10 cells and CCL2 and CCL5 from B16F10OVA cells (P < 0.01 for CCL2 and P < 
0.0001 for the others, Figure 2-3b). In order to confirm STING-dependent activation, we pre-
treated BMDCs with a STING inhibitor, C-178, followed by incubation with CDA formulations. 
Pre-treatment with C-178 significantly decreased the secretion of cytokines and chemokines 
induced by both free CDA and CDA@bMSN (Figure 2-3c), showing that CDA-mediated immune 
activation is indeed dependent on the STING pathway. 
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Figure 2-3. CDA@bMSN promotes cytokine and chemokine release from BMDCs and tumor cells. (a) Mouse BMDCs and 
(b) mouse melanoma cell lines, B16F10 and B16F10OVA, were treated with 10 µg/ml of CDA for 6 hr in vitro. Supernatants 
were assessed by ELISA for cytokines and chemokines. (c) BMDCs pre-treated for 1 hr with 0.5 µM of a STING inhibitor, C-
178, followed by treatment with 10 µg/ml of CDA for 6 hr. Data are presented as mean ± SEM, showing representative results 
from two independent studies with n = 3-4. **p < 0.01, ***p < 0.001, ****p < 0.0001 analyzed by analyzed by one-way or two-
way ANOVA with Tukey’s HSD multiple comparison post hoc test. 
 
Next, anti-tumor effects of CDA@bMSN was investigated in a murine melanoma model 
of B16F10OVA. C57BL/6 mice were injected subcutaneously with 3x105 B16F10OVA cells on 
the right-side flank. When tumors reached > 100 mm3 on day 6 after tumor inoculation, we 
performed a single intratumoral administration of 2 µg CDA in either bMSN or free form (Figure 
2-4a). Interestingly, both free CDA and CDA@bMSN treatments were able to induce regression 
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of established tumors with minimal tumor volume by day 14 (Figure 2-4b). However, 50% of 
mice in the free CDA-treated group quickly relapsed and had to be euthanized by day 30. In stark 
contrast, 100% mice in the CDA@bMSN treatment group remained tumor free for the duration of 
the study (Figure 2-4c). To understand the differences between the free CDA and CDA@bMSN 
treatment groups, we analyzed the levels of cytokines and chemokines as well as various immune 
cell subsets. In line with our in vitro results (Figure 3), after 3 hours of intratumoral administration, 
CDA@bMSN induced strong release of IFN-β, CXCL10, CCL2, and CCL5 in TME and serum 
(Figure 2-4d,e). Notably, even after 24 hr of administration, higher levels of CXCL10 and CCL2 
were detected within the TME for the CDA@bMSN group, compared with free CDA group (P < 
0.05, Figure 2-4d), suggesting sustained immune activation mediated by bMSN. 
We also investigated the effects of CDA treatment on the innate and adaptive immune 
responses. Intratumoral administration of CDA@bMSN led to robust activation of DCs within the 
TME, as evidenced by upregulation of CD86 within 3 hr and CD40 within 24 hr post treatment 
(Figure 2-4f). There was a trend for higher expression levels of CD86 and CD40 on DCs after 24 
hr of treatment with CDA@bMSN, compared with free CDA (Figure 2-4f) although their 
differences were not statistically significant. While free CDA treatment induced transient 
upregulation and down-regulation of CD107α, a degranulation marker, on intratumoral NK cells, 
CDA@bMSN treatment led to sustained expression of CD107α on intratumoral NK cells for up 
to 24 hr (P < 0.5, Figure 2-4g). By 24 hr of CDA@bMSN treatment, we also observed activation 
of NK cells in the circulation, as shown by increased levels of CD107α and NKG2D (83, 84) 
(Figure 2-4h). 
Intratumoral injection of free CDA significantly decreased the number of CD8+ T cells 
within the tumor by 24 hr post CDA injection, compared with no treatment group (P < 0.05, Figure 
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2-4i). This is in line with the literature reporting decreased tumor-infiltration of lymphocytes after 
intratumoral administration of free STING agonist (71, 81). In contrast, intratumoral 
CDA@bMSN treatment resulted in significantly higher number of intratumoral CD8+ T cells at 
24 hr time point, compared with free CDA (P < 0.01, Figure 2-4h), suggesting that bMSN-
mediated CDA delivery reversed the decrease in intratumoral infiltration of CD8+ T cells 
associated with free CDA (71, 81). CDA@bMSN treatment also significantly increased the 
expression of a degranulation marker, CD107α, on intratumoral CD8+ T cells by 24 hr, compared 
with untreated control (P < 0.05, Figure 2-4j). Overall, these results suggest that bMSN-mediated 
delivery of CDA amplifies the magnitude and duration of cytokine and chemokine release within 
TME and potently activates intratumoral DCs, NK cells, and CD8+ T cells, thus leading to 
regression of established tumors. 
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Figure 2-4. A single intratumoral treatment with CDA@bMSN exerts potent anti-tumor efficacy. (a) C57BL/6 mice were 
subcutaneously injected with 3x105 B16F10OVA cells on the right-side flank. After 6 days, each mouse received intratumoral 
injection of 2 µg CDA as a soluble or bMSN formulations. After 3 or 24 hr, blood sampling and tumor excision were performed. 
(b) Tumor growth curves and (c) animal survival are shown. (d) Cytokine levels within tumor tissues or (e) sera were measured by 
ELISA after 3 and 24 hr or 3 hr of CDA injection, respectively. Flow cytometric analyses were performed to examine (f) CD86 
and CD40 expression on DCs, (g,h) CD107α expression on NK cells and (i) the number of CD8+ T cells within the B16F10OVA 
TME for (f,g,i) and blood for (h). Data are presented as mean ± SEM, showing representative results from two independent studies 
with n = 3-4 for (b-c) and n = 5 for (d-j). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 analyzed by analyzed by one-way 




Having observed strong anti-tumor efficacy of CDA@bMSN, we evaluated CDA@bMSN 
in the setting of established B16F10 melanoma. As B16F10 is a poorly immunogenic, highly 
aggressive tumor model, we increased the dose of CDA@bMSN to 5 µg. C57BL/6 mice were 
inoculated s.c. with 3x105 B16F10 cells. When tumors were > 50 mm3 on day 6, we performed a 
single intratumoral administration of CDA either in a soluble or bMSN forms (Figure 2-5a). 
Whereas mice in the untreated control group quickly succumbed to B16F10 tumor with a median 
survival of 12 days, free CDA treatment slowed the B16F10 tumor growth and extended the 
median survival to 18 days (p < 0.01, Figure 2-5b,c). Compared with free CDA group, 
CDA@bMSN treatment further inhibited B16F10 tumor growth (p < 0.01, Figure 2-5b) and 
extended the median survival to 24 days (p < 0.05, Figure 2-5c), thus highlighting the therapeutic 
potential of CDA@bMSN. 
 
Figure 2-5. A single intratumoral treatment with CDA@bMSN exerts potent anti-tumor efficacy in B16F10 mouse 
melanoma model. (a) C57BL/6 mice were subcutaneously injected with 3x105 B16F10 cells on the right-side flank. After 6 days, 
each mouse received intratumoral injection of 5 µg free CDA or CDA@bMSN. (b) Tumor growth curves and (c) animal survival 
curves are shown. Data are presented as mean ± SEM, pooled from two independent studies. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001 analyzed by analyzed by two-way ANOVA with Tukey’s HSD multiple comparison post hoc test. Animal survival 




In summary, we have developed bMSN for efficient cytosolic delivery of STING agonists. 
While previous studies have reported various STING agonist-loaded NP systems (85-89) including 
liposomes and polymeric NPs, their fabrication and drug loading procedures are often complicated 
with multiple synthesis and separation steps, and many of these NP platforms have not been 
clinically tested. On the other hand, silica-based NPs offer a promising platform with 
biocompatibility, facile manufacturing process, and clinical safety (72, 73, 90). Notably, we have 
achieved > 90% loading of CDA into bMSN simply by admixing CDA with pre-formed bMSN 
for 1 hr. We show that bMSN carrying STING agonists improves STING activation by DCs and 
tumor cells and elicits potent innate and adaptive immune responses in vivo, leading to strong anti-
tumor efficacy and prolonged animal survival in murine models of melanoma. While the 
mechanisms underlying bMSN-mediated STING activation and subsequent cascades of innate and 
adaptive immune responses remain to be elucidated, our results suggest that bMSN is a 
biodegradable and biocompatible carrier for efficient delivery of STING agonists. It is also notable 
that the typical dose of STING agonists reported in the literature ranges from 10-240 µg, often 
used in combination with chemotherapeutic or immunotherapeutic agents (66, 71, 91-95). In 
contrast, we report that a single injection of CDA@bMSN at the dose of 5 µg or less exerted potent 
anti-tumor efficacy, thus highlighting the dose-sparing effect of the bMSN platform. Recent 
advances in cancer immunotherapy have generated intense research interest in drug delivery 
vehicles for improving immune activation (20, 26, 96, 97), and our bMSN system may offer a 
promising platform for delivery of immunomodulatory agents for cancer immunotherapy. 
Nevertheless, as our current studies have mainly focused on the acute responses mounted 
by innate immune cells after intratumoral CDA injection, our future studies will address the effects 
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of bMSN-based CDA delivery on adaptive immune responses and examine systemic delivery of 
CDA@bMSN. Further research is warranted to optimize the bMSN platform for the delivery of 
STING agonists in the context of combination cancer immunotherapy. 
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CHAPTER III. Personalized Combination Nano-immunotherapy for Robust Induction and 
Tumor Infiltration of CD8+ T Cells 
 
3.1. Abstract 
Identification of tumor-specific mutations, called neoantigens, offers new exciting opportunities 
for personalized cancer immunotherapy. However, it remains challenging to achieve robust 
induction of neoantigen-specific T cells and drive their infiltration into the tumor 
microenvironment (TME). Here, we have developed a novel polyethyleneimine (PEI)-based 
personalized vaccine platform carrying neoantigen peptides and CpG adjuvants in a compact 
nanoparticle (NP) for their spatio-temporally concerted delivery. PEI NP vaccine significantly 
enhanced activation and antigen cross-presentation of dendritic cells, resulting in strong priming 
of neoantigen-specific CD8+ T cells with the frequency in the systemic circulation reaching as 
high as 23 ± 7% after a single subcutaneous administration. However, activated CD8+ T cells in 
circulation exhibited limited tumor infiltration, leading to poor anti-tumor efficacy. Notably, local 
administration of stimulator of interferon genes (STING) agonist promoted tumor infiltration of 
vaccine-primed CD8+ T cells, thereby overcoming one of the major challenges in achieving strong 
anti-tumor efficacy with cancer vaccination. PEI NP vaccination combined with STING agonist 
therapy eliminated tumors in murine models of MC-38 colon carcinoma and B16F10 melanoma 
and established long-term immunological memory. Our approach provides a novel therapeutic 
strategy based on combination nano-immunotherapy for personalized cancer immunotherapy.
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3.2. Introduction 
Recent advances in genomics and proteomics are shedding new light on the tumor 
mutanome, revealing that every tumor has a unique set of driver and passenger mutations (17-19). 
Expression of neoantigens is, by definition, restricted to tumor cells as opposed to tumor-
associated antigens with shared expression among healthy and tumor cells. Thus, immunotherapy 
directed against neoantigens may allow for specific immunological targeting of tumor cells 
without self-tolerance. It has been the motive for an avalanche of cancer vaccine studies in the 
recent years. 
In 2017, first-in-man phase I clinical trials were reported in which patients with advanced 
melanoma were treated with neoantigen peptide vaccines following surgical resection of the 
tumour (24). Each of six patients received seven doses of 20 different neoantigen peptides mixed 
with poly(I:C) stabilized with poly-L-lysine (poly-ICLC) adjuvant(24); neoantigen vaccination 
induced CD4+ and CD8+ T cells specific for 58 (60%) and 15 (16%) of the 97 unique neoantigens 
identified across the six patients. Four patients showed no recurrence at 25 months after 
vaccination, and two patients had complete tumour regression after co-treatment with the 
checkpoint blockade agent anti-PD-1. Along with another phase I trial with neoantigen encoding 
mRNA vaccine detailed below(98), these seminal trials showed that personalized neoantigen 
vaccination, especially in combination with immune checkpoint blockade, can unleash the full 
cytotoxic potential of neoantigen-specific T cells to kill tumours with limited adverse effects, and 
underscored the clinical applicability of personalized neoantigen vaccines as a new therapeutic 
strategy for long-term protection against tumour relapse and metastasis. 
The tantalizing results of neoantigen vaccination galvanized the personalized 
immunotherapy field; nevertheless, producing potent anti-tumour neoantigens therapies in a safe, 
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effective, and personalized process is challenging: efficient delivery strategies are needed to 
enhance transport of neoantigens together with adjuvant molecules to lymph nodes; the amino acid 
composition of neoantigen peptides can have significant effects on their isoelectric properties, 
meaning that the administration of a cocktail of soluble peptides can lead to their precipitation, 
deposition in off-target tissues, or dissemination through the systemic circulation without 
preferential targeting to lymphoid tissues. Issues in vaccine delivery can result in only a minor 
fraction of the injected peptides reaching the target lymphoid tissues, reducing vaccine efficacy. 
Also, even if vaccination generates sufficient anti-tumor CD8+ T cells in the systemic circulation, 
intratumoral trafficking of CD8+ T cells is often limited, thus resulting in poor anti-tumor effects.  
Notably, tumor infiltration of CD8+ T cells is correlated with patient prognosis, as shown by recent 
retrospective analyses of clinical cases (31, 99-101). Also, tumors with sparse T cell infiltration 
are less responsive to immune checkpoint blockade (ICB) therapies designed to reinvigorate 
tumor-infiltrating lymphocytes (102). Such immunologically “cold” tumors have various 
immunosuppressive mechanisms to exclude or reprogram immune cells, thus shaping the tumor 
microenvironment (TME) to evade the immune surveillance (2, 103). While chemotherapy (104, 
105), oncolytic virus (106), and anti-angiogenic agents (107) have been applied to reverse 
immunosuppression and convert non-immunogenic “cold” tumors into T cell-inflamed “hot” 
tumors, it remains to be seen how to combine them effectively with cancer vaccination.  
Therefore, current personalized cancer vaccines using neoantigen peptides face two major 
problems. 1) Neoantigen peptides delivered in soluble forms generate suboptimal immune potency. 
2) Many tumors release insufficient levels of chemokines to attract circulating CD8+ T cells to the 
site of tumor. Thus, new approaches are needed to promote the induction of neoantigen-specific T 
cells and increase their tumor infiltration. 
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Here, to overcome these urgent challenges, we have developed a facile personalized 
nanoparticle vaccine using polyethyleneimine (PEI) that offers versatile functionality for modular 
incorporation of neoantigens and simple electrostatic assembly of CpG adjuvant. PEI NP vaccine 
significantly enhanced cellular uptake of antigens and adjuvant molecules to promote activation 
and antigen cross-presentation of dendritic cells (DCs), resulting in robust priming of neoantigen-
specific CD8+ T cell. However, despite high frequency of anti-tumor CD8+ T cells in the systemic 
circulation, we observed weak anti-tumor effect due to limited intratumoral trafficking of activated 
CD8+ T cells. STING is a pattern recognition receptor (PRR) that triggers NF-κB and IRF3 
pathways, leading to strong type I IFN responses (108), and recent studies have reported promising 
therapeutic efficacy of STING agonists for cancer treatment (66, 71). Here, we have demonstrated 
that intratumoral administration of STING agonist induced robust secretion of cytokines and 
chemokines that promoted T cell trafficking into the TME. When combined with PEI NP 
vaccination, treatment with STING agonist led to strong recruitment of vaccine-primed, 
neoantigen-specific CD8+ T cells into the TME, leading to significantly improved anti-tumor 
efficacy, compared to either treatment alone. These studies present a new combination nano-
immunotherapy for inducing neoantigen-specific T cells and their tumor infiltration for achieving 
potent anti-tumor efficacy.   
Specifically, we prepared personalized NP vaccine based on PEI by taking advantage of 
its versatile functionality for chemical conjugation and electrostatic complexation. PEI was grafted 
with PEG for enhancing colloidal stability and biocompatibility, followed by conjugation with 
CSS-modified neoantigen peptides via reduction sensitive disulfide bond. Because of the strong 
cationic characteristic of PEI, the simple mixture of PEI conjugates with anionic CpG formed a 
nanoscale condensate by electrostatic complexation. (Figure 3-1a). CpG was employed as an 
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adjuvant not only because of its strong anionic property but also for its potent immunostimulatory 
property (109). 
 
3.3. Materials and Methods 
Synthesis of PEI conjugates and CpG nanocomplex 
PEI-PEG was prepared using branched PEI (Sigma-Aldrich, molecular weight ~25,000) 
and methoxy poly(ethyleneglycol) propionic acid N-hydroxysuccinimide (Nanocs, molecular 
weight 5000) as reported previously 41. For PEI-PEG/CSS-antigen, PEI-PEG was dissolved in 
DMSO and added with 3-(2-Pyridyldithio)propionic acid N-hydroxysuccinimide ester (SPDP, 
Sigma-Aldrich) to create thiol-reactive disulfide bond. After stirring for 3h, the mixture was 
reacted with CSS-antigen overnight, followed by dialysis-purification using Amicon ultra 10 kDa 
MW cutoff centrifugal filters. CpG nanocomplex was formed by vigorously mixing CpG (CpG 
1826, Integrated DNA Technology) and PEI conjugate in PBS at the weight ratio 0.5, 1, 2, or 3.   
Animal studies 
Animals were cared for following federal, state and local guidelines. All experiments 
performed on animals were in accordance with and approved by the Institutional Animal Care and 
Use Committee (IACUC) at the University of Michigan, Ann Arbor. 5-6 weeks old female 
C57BL/6 mice were purchased from Jackson Laboratories. Tumor cells (6x105 MC-38 cells per 
mouse (1.2x106 for re-challenge study) and 3x105 B16F10 cells per mouse) were injected s.c. on 
the right flank of each mouse. Vaccines were administered s.c. at the tail-base on indicated days. 
Four days after the vaccination, CDA (dissolved in PBS; 0.5 µg for the MC-38 model and 5 µg for 
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the B16F10 model) was injected into tumors on the indicated days. Tumor sizes were measured 
using a caliper. 
In vitro BMDC studies 
BMDCs were collected from hind femurs of C57BL/6 mice, cultured with media 
supplemented with GM-CSF for 8-10 days as previously reported 42. For the analysis of cytokine 
secretion and proliferation by PEI NP, immature BMDCs were treated with free PEI-PEG/CSS-
Adpgk (PEI conjugate, 3 µg/ml), free CpG (1 µg/ml), or PEI NPs formulated at different weight 
ratios of PEI conjugate/CpG (1 µg/ml CpG and the respective amount of PEI conjugate). Cells 
were washed after 2 h, supplemented with fresh media, and further incubated for 24 h for the 
detection of IL-12p70 in cell culture media using ELISA, while BMDC proliferation was measured 
using a cell counting kit (CCK-8; Dojindo Molecular Technologies, Inc.).   
For studying CpG uptake by BMDCs, 5' phosphate group of CpG was tethered with 
ethylenediamine and subsequently labeled with Alexa Fluor® 647 NHS Ester (AF647-NHS, 
Invitrogen) as described before.41 In parallel, PEI conjugates were labeled with Alexa Fluor® 488 
NHS Ester (AF488-NHS, Invitrogen). BMDCs were then incubated with soluble formulation or 
PEI NPs at dose of 10 µg/ml CpG-AF467 and 20 µg/ml PEI conjugates-AF488 (equivalent of 10 
µg/ml for free Adpgk). At the indicated time points, cells were collected, washed with FACS buffer 
(1% BSA in PBS), and then subjected to flow cytometry for measuring fluorescence signals. To 
visualize cellular localization, BMDCs were grown onto 12 mm glass coverslips in 24 well plates 
at a density of 5 × 105 cells/well and treated with samples as above for 24 h. Cells were further 
incubated with Hoechst 33342 (5 μg/ml, Invitrogen) and Lysotracker Red DND-99 (100 nM, 
Invitrogen) for 30 min for the staining of nuclei and endolysosomes, respectively. Then, cells were 
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fixed with 4% formaldehyde in PBS and mounted on slide glass using ProLong™ Diamond 
Antifade Mountant (Invitrogen) for confocal microscopy (Nikon A1Rsi). 
For assessing activation and antigen cross-presentation, PEI NPs were constructed using 
PEI-PEG/CSS-SIINFEKL and CpG. BMDCs were incubated for 24 h with either soluble or PEI 
NP formulation of SIINFEKL and CpG (2 µg/ml SIINFEKL and 1 µg/ml CpG). Cells were then 
stained with antibody-fluorophore conjugates including CD40-APC (Invitrogen), CD86-PE/Cy7 
(BD Biosciences), and SIINFEKL/H-2kb-PE (Invitrogen) for 30 min at room temperature. Cells 
were washed with FACS buffer and analyzed using flow cytometry.  
For the analysis of cytokine secretion by BMDCs in response to CDA treatment, BMDCs 
were seeded at a density of 105 cells/well in a 96-well tissue culture plate and incubated overnight 
at 37 oC with 5% CO2. Cells were washed with PBS twice, and then added with 5 µg of CDA in 
200 µl of fresh culture media. Culture media were retrieved after 6 hrs for ELISA assay. 
Analyses of CD8+ T cells and cytokines in blood and tumor 
Blood was collected at the indicated time points by submandibular bleeding, treated with 
ACS lysing buffer (Gibco), and washed with PBS to obtain PBMCs. For TME analysis, tumor 
tissues were excised from tumor-bearing mice, cut into small pieces (1-2 mm) with scissors, and 
treated with 1 mg/ml of collagenase A (Sigma-Aldrich) and 100 IU of DNase I (Sigma-Aldrich) 
for 30 min at 37 oC with continuous shaking. Samples were placed on top of 40 µm strainers and 
mashed through with a plunger, followed by centrifugation at 1000 g for 5 min. The cell pellet was 
resuspended and washed twice with PBS by centrifuging at 1500 g for 3 min. PBMCs and tumor 
cells were stained with a live/dead staining dye (eBioscience) and fluorophore-labeled antibodies 
including CD3-FITC (Biolegend), CD8-APC (BD Biosciences), and Adpgk tetramer-PE (NIH 
Tetramer Core Facility), fixed with 2% formaldehyde, and then suspended in FACS buffer for 
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flow cytometry. Blood sera and tumor tissue supernatants were separately collected for detection 
of cytokines using ELISA. 
Statistical analysis 
Statistical analysis was performed with Prism 7.0e (GraphPad Software). Statistical 
comparisons were performed using one-way ANOVA followed by Tukey’s HSD multiple 
comparison post hoc test or two-way ANOVA followed by Sidak’s multiple comparisons test, as 
indicated in the figure legends. Animal survival was analyzed by the log-rank (Mantel−Cox) test. 
Statistical significances are indicated as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. 
 
3.4. Results and Discussion 
PEI-PEG conjugate was synthesized by conjugating methoxy poly(ethyleneglycol) 
propionic acid N-hydroxysuccinimide (methoxy-PEG-NHS) to the primary amine of PEI. The 
stoichiometry PEI:PEG was controlled to 1:15, which was reported to diminish cytotoxicity of 
PEI.(110, 111) The conjugation was confirmed by quantification of free amine groups using 2,4,6-
trinitrobenzene sulfonic acid (data not shown). To prepare a personalized NP vaccine, we 
employed Adpgk, a neo-epitope identified in MC-38 mouse colon adenocarcinoma.(112) PEI-PEG 
was incubated with 3-(2-pyridyldithio)propionic acid N-hydroxysuccinimide ester (SPDP) at room 
temperature (RT) for 3 hr for amine-to-sulfhydryl cross-linking, followed by overnight incubation 
with CSS-Adpgk. The resulting PEI-PEG/CSS-Adpgk conjugate was analyzed by gel permeation 
chromatography (GPC). As shown in Figure 3-1b, PEI-PEG/CSS-Adpgk had a major elution peak 
at 15 min; however, this particular peak was absent in the PEI-PEG conjugate, suggesting 
successful conjugation of Adpgk onto PEI-PEG. A brief treatment (~5 min) with dithiothreitol 
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(DTT) delayed the elution of PEI-PEG/CSS-Adpgk by ~0.9 min to be overlapped with the peak of 
free CSS-Adpgk + DTT sample (Figure 3-1b), indicating efficient release of CSS-Adpgk from 
PEI-PEG/CSS-Adpgk in a reduction sensitive manner.  
Incubation of PEI-PEG/CSS-Adpgk with CpG led to the formation of nanoparticles (PEI 
NPs). Dynamic light scattering (DLS) measurement showed that the hydrodynamic size of PEI 
NPs decreased with an increasing feed amount of CpG, resulting in 40 – 50 nm Z-average size and 
0.2 – 0.3 polydispersity index with the PEI conjugate/CpG weight ratio of > 1 (Figure 3-1c). In 
addition, the zeta potential values of PEI NPs were between those of free PEI conjugates and free 
CpG with almost neutral charges (Figure 3-1d), thus suggesting PEI/CpG charge compensation 
and PEG surface passivation. To assess the impact of complexation on immune activation by CpG, 
bone marrow-derived dendritic cells (BMDCs) were incubated with PEI NPs, and IL-12p70 
secretion and cellular viability were measured. PEI NPs formulated at the PEI-conjugate/CpG 
weight ratio of 1 or 2 promoted higher amount of IL-12p70 and proliferation of BMDCs, compared 
to PBS and free CpG (Figure 3-1e,f). In contrast, PEI conjugate alone did not induce the secretion 
of IL-12p70 nor proliferation of BMDCs, which indicated the crucial role of CpG in immune 
activation by PEI NPs. PEI NPs formulated at the PEI conjugate/CpG weight ratio of 2 exhibited 
relatively uniform size of 20 – 30 nm under transmission electron microscope (Figure 3-1g), which 
correlated well with the DLS measurements. Based on these results, PEI NPs formulated at the 
PEI conjugate/CpG weight ratio of 2 was chosen for the subsequent studies. 
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Figure 3-1. Synthesis and characterization of PEI NPs. (a) Schematic drawing of PEI nanoparticle vaccine formation. PEGylated 
PEI was conjugated with CSS-antigen via disulfide linkage and then condensated with CpG by electrostatic complexation to form 
PEI NPs. (b) GPC chromatograms, indicating the formation of PEI-PEG/CSS-Adpgk conjugate. (c) Hydrodynamic size and (d) 
surface charge of PEI NPs synthesized in different PEI conjugate:CpG weight ratios, as measured by DLS and zeta potential. (e) 
IL-12p70 secretion and (f) viability of mouse BMDC after incubation with PEI conjugate, CpG, or PEI NPs. (g) PEI NPs composed 
of a PEI conjugate:CpG weight ratio of 2:1 were imaged using TEM after 2% uranyl acetate staining. Scale bar = 100 nm. Data are 
presented as mean ± SEM. ***p < 0.001, ****p < 0.0001, analyzed by one-way ANOVA, followed by Tukey’s HSD multiple 
comparison post hoc test. 
 
Next, we investigated the impact of PEI NPs on DC uptake and subsequent activation and 
antigen presentation. Fluorophore-labeled CpG was formulated into PEI NPs for fluorescence-
based analysis of NP uptake by BMDCs. PEI NPs promoted the uptake of CpG as early as after 2 
h of incubation and showed > 30-fold increase over 72 hr, compared to free CpG (Figure 3-2a). 
The presence of Adpgk or CSS-Adpgk peptide admixed with CpG did not affect the uptake of 
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CpG, showing comparable levels with free CpG treatment alone. We further examined cellular 
uptake using confocal microscopy and confirmed that BMDCs incubated with PEI NPs displayed 
brighter CpG fluorescence within the endo-lysosomal compartments, compared with BMDCs 
incubated with free CpG (Figure 3-2b). Enhanced endo-lysosomal CpG delivery can potentiate  
engagement and activation of TLR9 receptors, which are located within the endo-lysosomes (113). 
We also investigated maturation and antigen presentation of BMDCs by employing SIINFEKL 
peptide, a MHC-I-restricted epitope of ovalbumin protein. BMDCs were incubated with PEI NPs 
consisting of PEI-PEG/CSS-SIINFEKL conjugates or control soluble formulations, followed by 
flow cytometric analysis. PEI NPs significantly increased the expression of co-stimulatory markers, 
including CD40 and CD86, on BMDCs (Figure 3-2c).  Next, cells were stained with 25-D1.16 
monoclonal antibody that recognizes SIINFEKL peptide complexed with H-2Kb MHC-I molecule 
(H-2Kb-SIINFEKL). Admixture of soluble SIINFEKL + CpG increased the expression of H-2Kb-
SIINFEKL within 8 h, which rapidly declined to the baseline level after 24 h (Figure 3-2d). In 
contrast, PEI NPs significantly increased antigen presentation after 24 h, as shown by highly 
elevated levels of H-2Kb-SIINFEKL, compared to SIINFEKL + CpG (p < 0.0001, Figure 3-2d). 
Thus, despite the slow kinetics, PEI NPs significantly increased the cumulative extent of antigen 
presentation, compared with soluble formulations. Taken together, these results show that PEI NPs 
promote cellular uptake of antigen and CpG, leading to enhanced DC activation, maturation, and 
antigen presentation, compared with their free admixture. 
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Figure 3-2. PEI NP promotes cellular uptake of antigen and CpG by DCs and improves DC maturation and antigen cross-
presentation. a-b) BMDCs were incubated in vitro with fluorophore-labeled CpG in the indicated formulations, and fluorescence 
signals were measured using (a) flow cytometry and (b) confocal microscopy (scale bar = 50 µm). (c-d) BMDCs were incubated 
with CpG, SIINFEKL + CpG, CSS-SIINFEKL + CpG, or PEI NP, and (c) DC activation and (d) antigen presentation were 
measured by staining cells with c) anti-CD86 and anti-CD40 antibodies or (d) anti-H-2Kb-SIINFEKL antibody, respectively, 
followed by flow cytometry. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, analyzed 
by two-way ANOVA, followed by Tukey’s HSD multiple comparison post hoc test. Asterisks represent comparison between PEI 
NP vs. Adpgk + CpG in (a), and between PEI NP vs. SIINFEKL + CpG in (c) and (d). 
 
Next, we examined the immunogenicity and anti-tumor efficacy of PEI NPs in vivo. 
C57BL/6 mice were injected subcutaneously (s.c.) with 6x105 MC-38 mouse colon carcinoma 
cells on the right flank on day 0. On day 7 when tumors were palpable, mice were vaccinated with 
various doses of PEI NPs composed of PEI-PEG/CSS-Adpgk conjugates and CpG (NP Vacc) via 
s.c. injection at tail base (Figure 3-3a). Soluble vaccines composed of free Adpgk and CpG (Sol 
Vacc) at the corresponding doses were used as control groups. To assess the priming of antigen-
specific CD8+ T cells, peripheral blood mononuclear cells (PBMCs) were collected 7 days after 
the vaccination, and the frequencies of Adpgk-specific CD8+ T cells were measured by the 
tetramer assay. NP Vacc induced a dose-dependent increase in the frequency of Adpgk-specific 
CD8+ T cells in peripheral blood (Figure 3-3b).  Notably, a single vaccination with NP Vacc at 
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1x dose (containing 10 µg of Adpgk peptide + 15 µg CpG) promoted clonal expansion of Adpgk-
specific CD8+ cells as high as 23 ± 6.9% among all CD8+ T cells in PBMCs, representing 3-fold 
enhancement compared with 1x dose of Sol Vacc (p < 0.05, Figure 3-3b). However, despite this 
significant expansion of neoantigen-specific CD8+ T cells in the systemic circulation, we did not 
observe meaningful anti-tumor effect for any of the vaccine groups (Figure 3-3c). Since successful 
cancer immunotherapy requires sufficient infiltration of anti-tumor T cells into the TME (114) we 
analyzed the TME for the frequency of CD8+ T cells. The total number of tumor-infiltrating CD8+ 
T cells in the TME was similar for all the treatment groups (Figure 3-3d). Although NP Vacc 
induced a slight increase in the number of Adpgk-specific CD8+ T cells, compared with PBS 
(Figure 3-3e), there was no statistical difference between the NP Vacc and Sol Vacc groups. Taken 
together, NP Vacc effectively expanded tumor-specific CD8+ T cells in the systemic compartment, 




Figure 3-3. PEI NP elicits tumor-specific CD8+ T cell responses in the systemic compartment but fails to inhibit MC-38 
tumor growth (a) Timeline of experiment. (b) C57BL/6 mice were inoculated at s.c. flank with 6x105 MC-38 colon carcinoma 
cells on day 0 and vaccinated at s.c. tail base on day 7 with increasing doses of vaccines. Neoantigen-specific CD8+ T cell levels 
in blood circulation were quantified on day 14 by tetramer staining and flow cytometry. (c) Shown are the average MC-38 tumor 
growth curves. (d-e) Numbers of tumor-infiltrating (d) CD3+CD8+ T cells and (e) tetramer+CD3+CD8+ T cells were measured 
on day 14. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, and ****p < 0.0001, analyzed by one-way ANOVA, followed 
by Tukey’s HSD multiple comparison post hoc test. 
 
STING has been reported to promote tumor infiltration of peripheral T cells through the 
type I interferon (IFN) pathway (115, 116). Based on these studies, we investigated whether 
STING agonist can recruit vaccine-primed circulating CD8+ T cells into tumors. First, we 
examined whether cyclic-di-adenosine monophosphate (CDA), a potent STING agonist, can 
induce secretion of chemokines essential for recruitment of T cells. BMDCs treated with CDA in 
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vitro produced increased levels of CXCL10, CCL2, CCL3, and CCL5 (Figure 3-4a). When CDA 
was administered directly into MC-38 tumors in vivo, this led to increased serum concentrations 
of IFN-β, CXCL10, CCL2, and CCL5 in a dose-dependent manner (Figure 3-4b). Intratumoral 
(i.t.) administration of CDA at the dose range of 1-20 µg was well tolerated, and mice did not show 
any abnormal change in body weight (Figure 3-4c).  
 
Figure 3-4. In vitro and in vivo effects of CDA treatment. (a) CDA (5 µg/ml) was treated to mouse BMDCs for 6 hours and 
culture media were analyzed for the levels of chemokines by ELISA. (b) Serum chemokine/cytokine concentrations 3 hours after 
intratumoral injection of CDA. Mice with no tumor did not receive CDA injection. (c) Body weight change after CDA injection. 
For 1 and 5 µg CDA, mice received injections every 3 days for three times and for 20 µg, only one injection was performed. Initial 
injections were done on day 8 post tumor injection. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 and 




Next, we investigated the effects of i.t. administration of CDA on vaccine-primed CD8+ T 
cells. C57BL/6 mice were inoculated with 6x105 MC-38 cells at s.c. flank. On day 7 when tumors 
were palpable, mice were s.c. vaccinated with NP Vacc, Sol Vacc, or PBS, followed by i.t. 
injection of CDA on day 11 (Figure 3-5a). Analyses of PBMCs on day 14 for the frequency of 
tumor-specific CD8+ T cells indicated that CDA mono-therapy induced weak anti-tumor CD8+ T 
cells in the systemic circulation (Figure 3-5b). Additional i.t. administration of CDA followed by 
s.c. NP Vacc or Sol Vacc slightly increased the mean frequency of vaccine-primed tumor-specific 
CD8+ T cells in circulation, but the increases were not statistically significant (Figure 3-5b). In 
stark contrast NP Vacc + CDA potently increased the number of CD3+CD8+ T cells in the TME 
(Figure 3-5c) and achieved 10.9-fold (p < 0.0001), 3.6-fold (p < 0.001), and 3.7-fold (p < 0.001) 
higher numbers of intratumoral neoantigen-specific CD8+ T cells, compared with CDA alone, NP 
Vacc alone, or Sol Vacc + CDA, respectively (Figure 3-5d). On the other hand, Sol Vacc + CDA 
had a minor effect on the level of CD8+ T cells in the TME (Figure 3-5c,d), probably due to 
weaker priming of CD8+ T cells by Sol Vacc. Moreover, NP Vacc + CDA significantly elevated 
the intratumoral concentration of IFN-γ (Figure 3-5e), which is a pleiotropic cytokine involved in 
cellular migration and effector functions of T cells during tumor rejection (117-121). We also 
monitored the effect of Vacc + CDA combination therapy on tumor growth and survival of MC-
38-bearing mice. MC-38 tumor bearing mice were vaccinated with either NP Vacc or Sol Vacc on 
day 7, followed by i.t. administration of CDA on days 11, 14, and 17 (Figure 3-5f). Sol Vacc + 
CDA slowed the average tumor growth, but the majority of animals succumbed to tumor growth 
by day 50 with 32% survival rate (Figure 3-5g,h). Importantly, NP Vacc + CDA exhibited 
remarkable anti-tumor efficacy, leading to robust tumor regression and complete tumor 
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elimination in ~70% of animals (Figure 3-5g,h). In addition, 100% of the survivors from the NP 
Vacc + CDA group were resistant to tumor re-challenge with 1.2x106 MC-38 cells injected in the 
contralateral s.c. flank on day 90 (Figure 3-5i), showing long-term immunological memory 
response. Overall, these results demonstrate that CDA promotes tumor trafficking of antigen-
specific CD8+ T cells primed by NP Vacc, leading to potent anti-tumor efficacy and long-term 
memory response against tumor relapse. 
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Figure 3-5. Combination of PEI NPs and STING agonist elicits tumor-specific CD8+ T cells in peripheral blood and the 
TME, leading to robust anti-tumor efficacy. (a) Timeline of experiment. C57BL/6 mice were inoculated at s.c. flank with 6x105 
MC-38 colon carcinoma cells on day 0 and vaccinated at s.c. tail base on day 7 with the indicated vaccines. A subset of animals 
also received intratumoral administration of 0.5 𝜇g CDA on day 11. On day 14, animals were analyzed for (b) Adpgk-
tetramer+CD8+ T cells within PBMCs, (c) tumor-infiltrating CD3+CD8+ T cells, and (d) tumor-infiltrating Adpgk-
tetramer+CD3+CD8+ T cells by flow cytometry. (e) Concentrations of IFN-γ were measured in tumors using ELISA. (f) Timeline 
of experiment. C57BL/6 mice inoculated at s.c. flank with 6x105 MC-38 colon carcinoma cells on day 0 were vaccinated on day 7 
via s.c. tail base. These mice received intratumoral administration of 0.5 𝜇g CDA on days 11, 14, and 17. Shown are (g) the average 
 45 
tumor growth curves and (h) animal survival. (i) Tumor growth curve after re-challenging survivors with MC-38 cells. Mice were 
re-challenged with 1.2x106 MC-38 cells by subcutaneous injection on the left-side flanks 90 days after the initial tumor inoculation. 
Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, analyzed by (b-e) one-way ANOVA 
followed by Tukey’s HSD multiple comparison post hoc test or (g,i) two-way ANOVA followed by Sidak’s multiple comparisons 
test. (h) The survival curves were analyzed by the log-rank (Mantel−Cox) test. 
 
Lastly, we sought to demonstrate the therapeutic potential and generality of NP Vacc + 
CDA combination therapy using B16F10 melanoma model, which is highly aggressive and 
resistant to conventional immunotherapies (122, 123). M27 peptide, a MHC class I-restricted 
neoantigen identified in B16F10 cells (124), was utilized to prepare PEI-PEG/M27 conjugates and 
subsequently formulated into NP Vacc with CpG as described earlier. C57BL/6 mice were 
inoculated at s.c. flank with 3 x 105 B16F10 tumor cells and vaccinated at s.c. tail base with NP 
Vacc on day 4, followed by i.t. administration of CDA on days 8, 11, and 14 (Figure 3-6a). 
Proliferation and activation of M27-specific CD8+ T cells were analyzed by IFN-γ ELISPOT assay 
performed on day 11 using splenocytes. NP Vacc elicited robust M27-specific IFN-γ+ CD8+ T 
cells, generating 57-fold higher ELISPOT responses than CDA mono-therapy (p < 0.0001, Figure 
3-6b). Whereas combination CDA treatment slightly decreased the frequency of M27-specific 
IFN-γ+ T cells in spleen (Figure 3-6b), it significantly increased the concentrations of IFN-β, 
CCL5, and CXCL10 in tumor (Figure 3-6c), compared with NP Vacc alone. In parallel, we 
monitored animals for tumor growth and survival (Figure 3-6d,e). As B16F10 melanoma is a 
poorly immunogenic (122, 123), NP Vacc alone failed to slow the tumor growth or extend the 
animal survival (Figure 3-6d,e). While CDA mono-therapy slightly delayed the tumor growth, all 
mice succumbed to tumor growth within 35 days. On the other hand, NP Vacc + CDA exhibited a 
remarkable anti-tumor efficacy, eradicating B16F10 tumors in 100% of treated mice (Figure 3-
6d,e). Overall, these results showed that PEI NP vaccine + CDA combination therapy exerts potent 
anti-tumor efficacy against even poorly immunogenic tumors.  
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Figure 3-6. PEI NP vaccine plus CDA combination therapy regresses poorly immunogenic B16F10 melanoma. a) Timeline 
of experiment. While tumor growth and survival of B16F10-bearing mice were monitored, subsets of mice were sacrificed on day 
11 for ELISPOT and ELISA analyses using spleens and tumor samples, respectively. b) Neoantigen peptide (M27)-specific cells 
within splenocytes were detected with IFN-γ ELISPOT assay. c) Cytokine concentrations in tumor measured by ELISA. d) Tumor 
growth and e) survival curves of B16F10 tumor-bearing mice. Asterisks in d) indicate statistical comparison between CDA and NP 
Vacc + CDA. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, and ****p < 0.0001, analyzed by b,c) one-way ANOVA 
followed by Tukey’s HSD multiple comparison post hoc test or d) two-way ANOVA followed by Sidak’s multiple comparisons 




In conclusion, we have developed PEI-based NPs co-delivering CpG adjuvants and tumor-
specific neoantigen peptides for personalized cancer immunotherapy and showed that they elicit 
potent anti-tumor CD8+ T cell responses in the systemic circulation; however, this was not 
sufficient to inhibit tumor growth, in part due to poor tumor infiltration of activated CD8+ T cells. 
We demonstrated for the first time that local administration of STING agonist can significantly 
enhance infiltration of NP vaccine-primed CD8+ T cells into the TME by promoting secretion of 
T cell-attracting chemokines and cytokines, leading to robust tumor regression and long-term 
immunological memory. Our strategy of utilizing STING-based immunotherapy for potentiating 
NP-based cancer vaccines present a new combination nano-immunotherapy that is be widely 
applicable for combination cancer immunotherapy. 
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CHAPTER IV. Lipid-based Vaccine Nanoparticles for Induction of Humoral Immune 
Responses against HIV-1 and SARS-CoV-2 
 
4.1. Abstract 
The current health crisis of corona virus disease 2019 (COVID-19) highlights the urgent need for 
vaccine systems that can generate potent and protective immune responses. Protein vaccines are 
safe, but conventional approaches for protein-based vaccines often fail to elicit potent and long-
lasting immune responses. Nanoparticle vaccines designed to co-deliver protein antigens and 
adjuvants can promote their delivery to antigen-presenting cells and improve immunogenicity. 
However, it remains challenging to develop vaccine nanoparticles that can preserve and present 
conformational epitopes of protein antigens for induction of neutralizing antibody responses. Here, 
we have designed a new lipid-based nanoparticle vaccine platform (NVP) that presents viral 
proteins (HIV-1 and SARS-CoV-2 antigens) in a conformational manner for induction of antigen-
specific antibody responses. We show that NVP was readily taken up by dendritic cells (DCs) and 
promoted DC maturation and antigen presentation. NVP loaded with BG505.SOSIP.664 (SOSIP) 
or SARS-CoV-2 receptor-binding domain (RBD) was readily recognized by neutralizing 
antibodies, indicating the conformational display of antigens on the surfaces of NVP. Rabbits 
immunized with SOSIP-NVP elicited strong neutralizing antibody responses against HIV-1. 
Furthermore, mice immunized with RBD-NVP induced robust and long-lasting antibody  
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responses against RBD from SARS-CoV-2. These results suggest that NVP is a promising 
platform technology for vaccination against infectious pathogens. 
 
4.2. Introduction 
As shown during the current COVID-19 pandemic, reliable and efficient vaccine delivery 
systems are urgently needed for vaccine development against COVID-19 as well as other emerging 
pathogens (125, 126). Traditional vaccines based on the live attenuated virus and inactivated virus 
vaccines are potent activators of the immune system, but they are limited by potential viral 
reversion and long development and regulatory timeline. On the other hand, protein vaccines with 
favorable safety profiles have been widely used for prophylactic vaccination against various 
pathogens, such as hepatitis B and influenza viruses (127). Yet, protein subunit vaccines often fail 
to elicit potent and long-lasting immune responses.  
These challenges may be addressed by co-administering subunit protein vaccines with 
potent adjuvants (128), especially in nanoparticle formulations that allow for their co-delivery to 
antigen-presenting cells for strong immune activation (129). There are various nanoparticle 
vaccine platforms under development, including polymers (130, 131), gold (132, 133), silica (79, 
134), and others (44, 135). In particular, lipid-based nanoparticles are generally considered to have 
excellent biocompatibility and safety, and they have been used as a vaccine carrier to deliver 
mRNA (136), DNA (137-139), and peptides (140). However, for protein antigens, it remains 
challenging to preserve their conformational epitopes and achieve robust neutralizing antibody 
responses using nano-vaccines. In particular, conformational display of antigens in vaccine 
formulations is crucial as immunogens should present epitopes to which the immune cells 
recognize, interact, and generate immune responses. Here, we sought to address these challenges 
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by designing a new lipid-based nanoparticle vaccine platform (NVP) that can load and present 
viral proteins (HIV-1 and SARS-CoV-2 antigens) in a conformational manner for induction of 
antigen-specific antibody responses.  
In particular, previous studies on acquired immunodeficiency syndrome (AIDS) have 
revealed the presence of broadly neutralizing antibodies in a subset of AIDS patients (141, 142). 
As the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein (Env gp) has been 
identified to induce broadly neutralizing antibodies, various HIV-1 Env gp immunogens have been 
developed. Among them, BG505.SOSIP.664 (SOSIP) has emerged as a promising immunogen for 
inducing neutralizing antibodies against HIV-1 (143-145). SOSIP is derived from the BG505 HIV-
1 clade A virus, which was isolated from a 6-week-old infant who later developed broadly 
neutralizing antibodies (145, 146). The native form of the glycoprotein gp160 is cleaved into 
gp120 and gp41 subunits during HIV-1 entry into host cells. To utilize gp160 for vaccination 
purpose, the membrane-associated and cytoplasmic domains were truncated and stabilized by 
insertion of a disulfide bond (referred to as “SOS”) and an Ile/Pro (“IP”) substitution at residue 
559 (I559P), resulting in an immunogen termed as SOSIP (143-145). SOSIP self-assembles into a 
soluble HIV-1 Env trimer; therefore, nano-vaccine formulation with SOSIP should maintain the 
structural integrity and neutralizing epitopes of SOSIP.  
During the initial COVID-19 outbreak, the structural similarities between SARS-CoV and 
SARS-CoV-2 were discovered (147). It was subsequently revealed that spike glycoprotein (S 
protein) of SARS-CoV-2 was responsible for viral infection via interaction with angiotensin-
converting enzyme 2 (ACE2) receptors on human cell membranes and that the antibodies 
generated against the S protein effectively neutralize viral entry to human cells (42, 148). The 
receptor-binding domain (RBD) is the functional domain within the S protein that first engages 
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with ACE2, is considered a prime target for COVID-19 vaccine development, and can be produced 
as a recombinant antigen to generate directed antibody responses (149, 150).  
It should be noted that both SOSIP and RBD possess tertiary molecular structures through 
various bonds, including disulfide bond (41, 151), that are prone to denaturation if placed under 
harsh condition, e.g., extreme pH, temperature, and physical stress. While we have previously 
reported lipid-based vaccine nanoparticles that employ thiol-maleimide crosslinking reaction to 
form nanoparticles (152-155), they are not ideal for immunogens held together by disulfide bonds, 
such as in SOSIP. Therefore, we sought to design a new nano-formulation for loading HIV-1 
SOSIP and SARS-CoV-2 RBD while preserving epitopes for inducing antibody responses. We 
show that pre-formed lipid vesicles incubated with protein antigens, followed by complexation 
and stabilization of lipid layers with branched polyethyleneimine (PEI), forms a nanoparticle 
vaccine platform (NVP) capable of loading viral antigens in a conformational manner. NVP co-
loaded with antigens and monophosphoryl lipid A (MPLA, a potent Toll-like receptor-4 agonist) 
was readily taken up by dendritic cells (DCs) and promoted DC maturation and antigen 
presentation. NVP carrying SOSIP or RBD was recognized and surface-bound by neutralizing 
antibodies, indicating the conformational display of antigens on the surfaces of NVP. Rabbits 
immunized with SOSIP-NVP elicited neutralizing antibody responses against HIV-1. Moreover, 
mice immunized with RBD-NVP induced robust and durable antibody responses against RBD 
from SARS-CoV-2. These results suggest that NVP is a promising platform technology for 
vaccination against infectious pathogens. 
 
4.3. Materials and Methods 
Reagents 
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SOSIP proteins were kindly provided by Drs. John Moore and Rogier Sanders from Weill 
Medical College, Cornell University, New York. Recombinant RBD proteins were kindly 
provided by Dr. Janet Smith of University of Michigan, Ann Arbor. Antigen (SOSIP)-specific 
primary monoclonal antibodies b6 and PGV04 were kindly provided by the International AIDS 
Vaccine Initiative. Rabbit Anti-Mouse IgG H&L-HRP was purchased from Abcam. Goat Anti-
Mouse IgG1-HRP and Goat Anti-Mouse IgG2a-HRP were purchased from Southern Biotech. 
Following antibodies were used for antigen display assay: human IgG1 kappa isotype (EMD 
Millipore), PE-conjugated anti-human IgG (Fcγ) secondary antibody (ebioscience), Alexa Fluor 
488-labeled anti-human IgG1 Fc secondary antibody (Invitrogen), Anti-SARS-CoV-2 RBD 
Neutralizing Antibody, Human IgG1 (SAD-S35) (Acrobiosystems). 
Synthesis and characterization of nanoparticle vaccine platform (NVP) 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) (Avanti Polar Lipids), n-
(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine, dioleoyl (DOPE-NHS) (NOF 
America Corporation) and monophosphoryl lipid A (MPLA) (Avanti Polar Lipids), all dissolved 
in chloroform, were mixed in 50:50:0.5 molar ratio in a glass vial. Lipids were dried under nitrogen 
gas, followed by a further complete drying step by putting the vial inside a desiccator. The dried 
lipid film was rehydrated with 100 µl of bis-tris propane (BTP) buffer (pH 7.0) by vortexing for 
10 sec every minute for 7 min. The resulting multilamellar vesicles were probe tip-sonicated at 40% 
amplitude for 5 min while placed in ice. The resulting unilamellar vesicles (ULV) were mixed 
with 100 µl of either SOSIP (25 µg) - or RBD (20 µg)-containing BTP buffer and incubated in 37 
oC for 30 min under constant shaking. Branched PEI of 1800 Da (number-based average) (Sigma 
Aldrich) was added at 0.35:1 primary amine:NHS ratio (NHS groups present in liposome), and 
then the mixture was further incubated at 37 oC for 30 min. The resulting antigen-loaded NVP 
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suspension was centrifuged at 14,000 g for 5 min, then were washed with PBS twice, followed by 
final resuspension with 200 µl of PBS. The particles were transferred to deionized water for size 
and surface charge measurement using the Zetasizer Nano (Malvern, UK). The loading efficiencies 
of proteins in NVP were measured by sodium dodecyl sulphate–polyacrylamide gel 
electrophoresis (SDS-PAGE), followed by Coomassie Blue staining (for SOSIP and RBD). Gels 
were imaged with a gel doc machine, Fluorchem M Imaging System (Protein Simple). 
In vitro DC uptake assays 
Mouse BMDCs were isolated from bone marrow obtained from hind femurs of C57BL/6 
mice. Cells were cultured in media supplemented with GM-CSF for 10 days in 37 oC, 5% CO2. 
Mature BMDCs were seeded in 2x105 per well of a 96-well tissue culture plate (flow cytometry) 
or 1x105 per well of an 8-well chambered cover glass (confocal microscopy), incubated for at least 
6 hr for cell adhesion, and then treated with DQ-OVA (Invitrogen)-containing vaccine 
formulations for 1-24 hr. For flow cytometry analysis, cells were recovered after trypsin treatment 
for 10 min. Retrieved cells were incubated with anti-CD16/32 blocking antibody for 10 min in 
room temperature (RT), followed by incubation with anti-CD11c, anti-CD80, and anti-
SIINFEKL/MHC-I antibodies for 20 min in RT and a fixable viability dye (eFluor 450, 
eBioscience) for 10 min in RT. Cells were then fixed with 4% formaldehyde in PBS for 10 min, 
washed and resuspended in PBS containing 1% bovine serum albumin (BSA) and analyzed with 
a flow cytometer (Bio-Rad ZE5). For confocal microscopy, BMDCs were treated with DQ-OVA 
formulations for 4 hr, followed by three times of washing with PBS. Cells were then stained with 
0.1 µM Lysotracker (ThermoFisher L7528) and 1 µg/ml Hoechst (ThermoFisher H3570) in 37 oC 
for 30 min. After washing with PBS, cells were fixed with 4% formaldehyde in PBS for 15 min, 
followed by washing with PBS. Cells were then analyzed with Nikon A1Rsi confocal microscope. 
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Antigens display on NVP 
For assessing antigen display on NVP, 1,1´-dioctadecyl-3,3,3´,3´-
tetramethylindodicarbocyanine (DiD) (Invitrogen, 0.2 mol%) was added in the lipid composition 
of NVP. Fluorescence signal from DiD was used to normalize the amount of NVP for comparison 
between different formulations due to variance in the recovery of formulations. For SOSIP-NVP, 
SOSIP-specific antibodies, b6 and PGV04, were incubated with NVP, followed by washing in 
PBS and addition of PE-conjugated anti-human IgG (Fcγ) secondary antibody (ebioscience). For 
RBD-NVP, monoclonal neutralizing antibody (SAD-S35, Acrobiosystems) against SARS-CoV-2 
was treated (1:100 dilution), followed by washing in PBS (x3) and addition of Alexa Fluor 488-
labeled anti-human IgG1 Fc secondary antibody (1:50 dilution) (Invitrogen). Antibody incubations 
were performed at room temperature for 30 min with constant shaking. Resulting samples were 
measured with a fluorometer (Biotek Synergy Neo microplate reader) at excitation/emission 
wavelengths of 485 nm/528 nm and 630 nm/680 nm or by “NanoFACS” as we recently reported 
(153).  
In vivo vaccination study 
Animals were cared for following federal, state, and local guidelines. All experiments 
performed on animals were in accordance with and approved by the Institutional Animal Care and 
Use Committee (IACUC) at the University of Michigan, Ann Arbor. White New Zealand rabbits 
(6-8 weeks old females from Jackson Laboratory) were vaccinated subcutaneously at four sites on 
both caudal thighs (2 sites per side) with either soluble mixture SOSIP and MPLA or NVP co-
loaded with SOSIP and MPLA. Doses used for primary and boost injections were 30 µg SOSIP + 
50 µg MPLA and 12.4 µg SOSIP + 20.6 MPLA, respectively. Primary vaccination was injected 
on day 0, followed by boost vaccinations on days 28 and 84. 2-3 ml of blood was sampled from 
 55 
each rabbit via marginal ear vein on days 28, 56, 105 and 169, which was placed in room 
temperature undisturbed for 1 hr to induce coagulation, followed by centrifugation at 2,000 g for 
12 min at 4 oC to obtain serum. Rabbit immune sera were analyzed for neutralizing activities 
against homologous tier 1A (MW965.26) and 2 (BG505/T332N) viral entry using the TZM-bl cell 
assay, which measures transactivation of a luciferase reporter gene by an infecting virus (156, 157). 
BALB/c mice (6-8 weeks old females from Jackson Laboratory) were vaccinated subcutaneously 
at the tail-base on days 0, 14, and 28 with either soluble mixture RBD and MPLA or NVP co-
loaded with RBD and MPLA. PBS was included as a negative control. The dose used for each 
injection was 0.5 µg RBD and 1 µg MPLA. Blood was sampled from each mouse via 
submandibular vein on days 14, 28 and 42. Samples were collected in a gel-containing tube 
(Microvette 500 SER-GEL, Sarstedt Inc.), followed by centrifugation at 10,000 g for 5 min to 
obtain serum. Mouse immune sera were analyzed for RBD-specific IgG, IgG1, and IgG2a antibody 
titers using ELISA. Briefly, RBD protein was coated on 96-well ELISA plates (0.1 µg/well) and 
serially diluted sera samples were added. After one hr of incubation and multiple washings, horse 
radish peroxidase (HRP)-labeled secondary antibodies were added and further incubated for 1 hr 
in room temperature. Secondary antibodies used included rabbit anti-mouse IgG H&L-HRP 
(Abcam), goat anti-mouse IgG1-HRP (Southern Biotech) or goat anti-mouse IgG2a-HRP 
(Southern Biotech). Next, TMB substrate solution was added, and the reaction was stopped by the 
addition of NaF. The absorbance was measured at a 620 nm wavelength using a plate reader 
(Synergy Neo, BioTek). To measure antibody titers, titration curves were drawn based on the 
absorbance and the dilution factor, from which half maximal effective concentration (EC50) values 
were calculated using a software Gen5 (BioTek). 
Lymph node trafficking study 
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BALB/c mice were subcutaneously injected at the tail-base with PBS, soluble antigen + 
MPLA, or antigen-MPLA-NVP. As a model antigen for investigating lymph node trafficking, 
Alexa Fluor 647-labeled ovalbumin (AF647OVA) (Invitrogen) was used. A dose consisting of 10 
µg of AF647OVA and 11 µg of MPLA was injected to each mouse. After 4, 8, 24 and 48 hr of 
injection, serum samples were collected for ELISA to measure proinflammatory cytokine levels. 
After 48 hr, draining lymph nodes were collected for fluorescence imaging to quantify the amount 
of antigen. Lymph nodes were placed in the imaging machine (IVIS spectrum, PerkinElmer) and 
imaged using 640 nm and 680 nm ex/em filters. Lymph nodes were then processed into single 
cells for flow cytometric analysis. Briefly, lymph nodes were homogenized with a mini-tissue 
homogenizer, then passed through a 40 µm strainer to collect single cells. After washing the cells 
twice with PBS (1% BSA), anti-CD16/32 Ab was added for 10 min at 4 oC, followed by the 
addition of anti-mouse CD80 Ab (FITC) (BD Biosciences), anti-mouse CD86 Ab (PECy7) 
(eBioscience), and anti-mouse CD11c Ab (PE) (BioLegend) Ab for 30 min at 4 oC. Then the cells 
were washed twice with PBS, stained for live/dead (EBioscience, Fixable viability dye eFluor 450), 
and fixed with 4% formaldehyde. Resulting cells were washed twice with PBS (1% BSA) and 
analyzed by flow cytometry. 
Blue native PAGE 
For Blue Native PAGE, samples were run on NativePAGETM Novex® Bis-Tris gel system 
(Life Technologies). Briefly, samples were diluted in Native PAGE sample buffer, bath sonicated 
to disrupt aggregates, and were incubated with N-Dodecyl β-D-maltoside (DDM, Invitrogen) at a 
1.11% working concentration for 30 min on ice. Immediately before loading onto gels (3%-12% 
Bis-Tris), Coomassie G-250 was added to the samples following manufacturer's instructions. Gels 
were run at room temperature using dark blue cathode buffer for approximately 100 min. Gels 
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were destained according to manufacturer's instructions, and protein migration was assessed by 
silver staining (Thermo Fisher). 
Statistical analysis 
The results are expressed as means ± SEM. Prism 7.0e (GraphPad Software) software was 
used for statistical analyses. Statistical comparisons were performed using either unpaired 
student’s t-test or one-way or two-way ANOVA, followed by Tukey's HSD multiple comparison 
test. Statistical significances are indicated as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 
0.0001. 
 
4.4. Results and Discussion 
Synthesis and characterization of NVP. 
We synthesized a nanoparticle vaccine platform (NVP) by adding viral antigens to pre-
formed unilamellar lipid vesicles, followed by incubation with branched PEI that allows for 
complexation and stabilization of vesicles into NVP via interaction between NHS-functionalized 
phospholipids and primary amine groups in PEI. Briefly, multilamellar vesicles were prepared by 
hydrating a lipid film composed of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), n-
(Succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine, dioleoyl (DOPE-NHS) and 
monophosphoryl lipid A (MPLA, a Toll-like receptor-4 agonist) (50:50:0.5 mol ratio). 
Multilamellar vesicles were tip sonicated to form into unilamellar vesicles, which then were mixed 
and surface-loaded with antigen proteins. Branched PEI (1,800 Da) was subsequently added in a 
primary amine:NHS ratio of 0.35:1 to induce complexation of lipid vesicles and nanoparticle 
formation by the reaction between the primary amines on PEI and the NHS groups on the 
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unilamellar vesicles (Figure 4-1a). The resulting NVP exhibited a hydrodynamic size of 200-400 
nm and a polydispersity index of 0.1-0.3 depending on the antigen added, with slightly negative 
surface charge as shown by dynamic light scattering (DLS) measurement (Figure 4-1b). 
 
Figure 4-1. Preparation and characterization of NVP. (a) Schematic drawing of NVP preparation process. (b) Mean 
hydrodynamic size, PDI, and surface charge of NVPs as measured by DLS.  Protein loading efficiency was calculated based SDS-
PAGE analysis. 
 
NVP improves antigen uptake by DCs and enhances DC activation and antigen presentation 
As a model antigen, DQ-labeled ovalbumin (DQ-OVA) was loaded to NVP to examine 
antigen delivery to and activation of DCs in vitro (Figure 4-2a-f) DQ is a self-quenched dye that 
emits fluorescence upon degradation after cellular entry (158). PAGE analysis showed efficient 
loading (~60%) of DQ-OVA to NVP (Figure 4-2g). BMDCs treated for 1 hr with NVP carrying 
DQ-OVA (DQ-OVA-NVP) exhibited a 2.72-fold increase in the DQ signal, compared with those 
treated with soluble DQ-OVA and MPLA mixture, as confirmed by flow cytometry (Figure 4-2a). 
A similar trend was observed over 24 hr (Figure 4-2b). As shown by confocal microscopy, 
BMDCs treated with DQ-OVA-NVP for 4 hr showed significantly higher DQ signal within the 
cytosol, with a high level of co-localization with lysosomes (Figure 4-2h). In addition, DQ-OVA-
NVP induced robust DC maturation, as shown by the up-regulation of CD80 co-stimulatory 
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marker on DCs within 1 hr of incubation (Figure 4-2c) and throughout 24 hr time window (Figure 
4-2d). Moreover, we examined antigen presentation on DCs by flow cytometry assay after staining 
DCs with a monoclonal antibody specific to an immunodominant OVA epitope (SIINFEKL) 
loaded in major histocompatibility complex-I (MHC-I) molecule. NVP-mediated DQ-OVA 
delivery led to significantly greater antigen presentation on DCs (Figure 4-2e-f). Taken together, 
these results show that NVP significantly increases DC uptake of vaccines, leading to improved 
DC activation and antigen presentation. 
 
Figure 4-2. NVP enhances antigen uptake, activation and antigen processing by dendritic cells in vitro. (a-g) BMDCs were 
treated with DQ-OVA and MPLA using the indicated formulations, and DQ-OVA signal was quantified by (a-b) flow cytometry 
after 1, 4, and 24 hr of incubation. BMDCs were also assessed for (c-d) CD80 expression and (e-f) antigen presentation of 
SIINFEKL on MHC-I. (g) SDS-PAGE image of DQ-OVA-loaded NVP. (h) After 4 hr of incubation, BMDCs were stained with 
LysoTracker and Hoechst, followed by confocal microscopy. Data are presented as mean ± SEM. **p < 0.01, ****p < 0.0001, 
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analyzed by one-way ANOVA (a,c,e) or two-way ANOVA (b,d,f), followed by Tukey’s HSD multiple comparison post hoc test. 
Asterisks in (b,d,f) indicate statistical comparison between DQ-OVA-NVP and DQ-OVA. 
 
NVP effectively delivers antigen to DCs in lymph nodes 
Next, we investigated NVP-mediated lymph node trafficking of antigen using a model 
antigen, Alexa Fluor 647 (AF647)-labeled ovalbumin (AF647OVA). Mice were given tail-base 
subcutaneous injection of PBS, soluble AF647OVA + MPLA, or AF647OVA-loaded NVP (OVA-
MPLA-NVP), followed by flow cytometry or ELISA analyses (Figure 4-3a). After 48 hr of 
vaccination, draining inguinal lymph nodes were visualized by IVIS fluorescence imaging. Mice 
administered with OVA-MPLA-NVP had significantly stronger AF647 signal in lymph nodes, 
compared with those treated with the soluble formulation (Figure 4-3b). Flow cytometric analysis 
showed that CD11c+ DCs in lymph nodes from the OVA-MPLA-NVP group exhibited signs of 
maturation, as shown by CD80 and CD86 staining (Figure 4-3c). Interestingly, among CD80+ 
and CD86+ DCs, the OVA-MPLA-NVP group had significantly higher mean fluorescence 
intensity of AF647OVA, compared with the soluble vaccine group (Figure 4-3d), showing robust 
DC-targeted delivery of antigen by NVP.  Lastly, the serum levels of proinflammatory cytokines, 
IL-6 and IL-12p40, were measured using ELISA. Serum concentrations of IL-6 and IL-12 were 
elevated at 4 hr and 8 hr post injection, respectively, for the soluble vaccine group (Figure 4-3e), 
whereas there was no spike of either cytokines in the NVP group. Taken together, these results 
showed that NVP provides an efficient and safe platform for antigen delivery to antigen-presenting 
cells in lymph nodes.  
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Figure 4-3. NVP improves antigen delivery to antigen-presenting cells in lymph nodes. (a) Mice were administered 
subcutaneously with PBS, soluble AF647OVA + MPLA, or AF647OVA-MPLA-NVP, followed by tissue analysis on the indicated 
time points. (b) Inguinal lymph nodes were excised and imaged for AF617OVA signal at 48 hr after vaccination. (c) CD11c+ DCs 
in inguinal lymph nodes were analyzed for CD80 and CD86 maturation markers. (d) CD11c+ DCs with or without upregulation of 
CD80 and CD86 were analyzed for AF647OVA. (e) At the indicated time points after vaccination, serum concentrations of IL-6 
and IL-12p40 were analyzed by ELISA. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, 
analyzed by (b,c) one-way ANOVA or (d,e) two-way ANOVA, followed by Tukey’s HSD multiple comparison test. 
 
Loading recombinant HIV envelope glycoprotein (SOSIP) into NVP 
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BG505.SOSIP.664 (SOSIP) is a recombinant HIV-1 envelope glycoprotein derived from 
the BG505 clade A virus. SOSIP is held together by a disulfide bond and self-assembles into a 
soluble HIV-1 Env trimer (Figure 4-4a). SOSIP is a promising immunogen for HIV-1 vaccine 
development, as shown by prior pre-clinical studies reporting SOSIP-mediated induction of 
neutralizing antibodies against HIV-1 (143, 144, 159). Here, we prepared NVP carrying SOSIP 
antigen and examined its efficacy to induce neutralizing antibody response against HIV-1. Using 
the procedure described above, we loaded SOSIP into NVP (SOSIP-NVP), which exhibited a 
hydrodynamic size of ~330 nm, as determined by DLS analysis (Figure 4-1b). PAGE-based 
quantification indicated a ~25% loading efficiency of SOSIP in NVP (Figure 4-4b).  Notably, it 
is crucial to maintain the conformational epitopes and trimeric structure of HIV-1 Env for the 
induction of broadly neutralizing antibody responses (160). Therefore, we examined whether 
SOSIP-NVP preserves the structure and epitopes of SOSIP during the vaccine formulation. Our 
non-reducing PAGE analysis performed on SOSIP retrieved from SOSIP-NVP indicated that 
SOSIP-NVP maintained the disulfide bond in SOSIP without disruption during the loading process 
(Figure 4-4b). SOSIP also appeared in the high molecular weight area in the PAGE gel, which 
may have been due to complexation with PEI and incomplete retrieval process from SOSIP-NVP. 
In addition, the preservation of quaternary structure of SOSIP trimer after NVP loading was 
examined by blue-native PAGE. Interestingly, application of a significant physical stress (e.g. tip 
sonication) while SOSIP trimer is present in solution induced dissociation of the trimer into 
monomer and dimer, demonstrating the delicate binding force between the subunits (Figure 4-4c, 
3rd lane). Thus, we modified the SOSIP-NVP preparation by adding SOSIP to the reaction mixture 
after any physical stresses were taken place, which resulted in the preservation of intact quaternary 
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structure after SOSIP-NVP formulation (Figure 4-4c, 5th lane). Nevertheless, these results 
indicated that SOSIP was effectively loaded into NVP.  
To further examine whether SOSIP was displayed on the surface of NVP with its epitopes 
remaining intact, we performed immunofluorescence directly on SOSIP-NVP. For this, we 
employed Env-specific human antibodies, PGV04 and b6, which recognize the CD4 binding site 
of Env. PGV04 and b6 are HIV-1 broadly neutralizing antibody and non-neutralizing antibody, 
respectively. PGV04 and b6 were incubated with SOSIP-NVP, followed by washing and another 
round of incubation with fluorophore-tagged anti-human IgG antibody. Then fluorescence signal 
on SOSIP-NVP was quantified to assess antibody binding (Figure 4-4d, e). SOSIP-NVP was 
readily recognized and bound by PGV04, a broadly neutralizing antibody, on a whole population 
level, as shown by a plate-based fluorescence measurement (Figure 4-4d). SOSIP-NVP was also 
bound by b6, a non-neutralizing antibody, but to a lesser extent than PGV04. We recently reported 
that antibody-binding on nanoparticles could be quantified on an individual nanoparticle-basis 
using “NanoFACS” (153). Using NanoFACS, we confirmed that PGV04 was bound to individual 
SOSIP-NVPs (Figure 4-4e), thus showing the homogenous display of SOSIP on the surfaces of 
SOSIP-NVPs. These results indicated the preservation of SOSIP epitopes after loading in NVP. 
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Figure 4-4. BG505.SOSIP.664 (SOSIP) protein and its display on NVP surface after loading. a) Genetic modifications from 
Env gp160 resulted in SOSIP, having truncation at residue 664, added glycan (indicated by *; T332N) and a disulfide bond, and 
other point mutations. MPER: membrane proximal region, TM: transmembrane domain, CT: cytosolic tail. b) Loading of SOSIP 
into NVP confirmed by non-reducing PAGE, followed by silver staining. c) Blue native PAGE showing intact SOSIP trimer before 
or after physical disruption as well as after loading in NVP using an optimized formulation condition. d-e) To examine SOSIP 
display on NVP, human anti-SOSIP antibodies, b6 and PGV04, were incubated with SOSIP-NVP and PE-labeled anti-human IgG 
antibody, followed by quantification of antibody binding by d) plate-based fluorescence measurement and e) individual 
nanoparticle-based flow cytometry. Data are presented as mean ± SEM. *p < 0.05, ***p < 0.001, analyzed by one-way ANOVA, 
followed by Tukey’s HSD multiple comparison post hoc test. 
 
SOSIP-NVP vaccination study in rabbits 
We performed immunization studies with SOSIP-NVP and examined their potency to 
generate neutralizing antibody response in rabbits. White New Zealand rabbits were immunized 
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on day 0 with 30 µg SOSIP and 50 µg MPLA, followed by two boost immunizations on days 28 
and 84, each with 12.4 µg SOSIP and 20.6 µg MPLA (Figure 4-5a). SOSIP and MPLA were 
administered subcutaneously either in SOSIP-NVP or soluble formulations. Sera samples 
collected on days 28, 56, 105 and 169 were assessed for neutralization against HIV-1 viral entry 
to TZM-bl cells using heterologous tier 1A virus (MW965.26, clade C) and autologous tier 2 virus 
(BG505/T332N) (161, 162). On Day 56 and more noticeably on Day 105, immune sera from the 
SOSIP-NVP vaccine group showed strong neutralizing activity against heterologous titer 1A 
MW965.26 virus (Figure 4-5b), with a trend for increasing neutralizing activity compared with 
the soluble vaccine group. Day 169 immune sera also showed neutralizing activity, although 
dampened compared with day 105, against MW965.26 (Figure 4-5b). As BG505.SOSIP.664 
trimer is derived from HIV-1 clade A, our results showing neutralizing activity against MW965.26 
HIV-1 clade C virus indicated that SOSIP-NVP elicited a cross-neutralizing antibody response. 
Furthermore, day 105 immune sera from SOSIP-NVP immunized rabbits exhibited high 
neutralizing antibody titers against neutralization-resistant tier 2 BG505/T332N virus, whereas the 
soluble vaccine group induced no neutralizing antibody response (Figure 4-5c). Moreover, there 
was also a trend for higher neutralizing antibody titers against autologous BG505/T332N up to 
day 169 (Figure 4-5c). As it has been challenging to produce vaccines capable of neutralizing 
against a tier 2 virus, even an autologous one such as BG505/T332N virus, these results show the 




Figure 4-5. Vaccination of rabbits using SOSIP-NVP enhances neutralizing antibody titers in sera against homologous virus 
in vitro. (a) Rabbits were prime vaccinated on D0 and boost vaccinated on D28 and D84, followed by blood sampling on D28, 
D56, D105 and D169. (b-c) Immune sera were analyzed for neutralization of (b) tier 1A and (c) tier 2 homologous viruses in vitro. 
Data are presented as mean ± SEM. *p < 0.05, analyzed by unpaired student’s t-test. 
 
NVP carrying receptor-binding domain (RBD) of SARS-CoV-2 
Motivated by the promising results of SOSIP-NVP, we sought to apply the NVP 
technology for COVID-19 vaccine development. According to previous studies, the spike protein 
(S protein) of SARS-CoV-2 is responsible for the interaction with ACE2 receptors on the human 
cells which leads to viral infection. Inducing antibody response against S protein therefore is an 
effective strategy to neutralize SARS-CoV-2 (42, 148). The receptor-binding domain (RBD) is the 
functional region within the S protein that engages ACE2, and has been suggested as a great target 
for vaccines against SARS-CoV-2 (149, 150). In addition, our analysis on genetic sequence 
comparison between SARS-CoV-2 variants reported on National Center for Biotechnology 
Information (NCBI) as of August 2020 and the original SARS-CoV-2 that appeared in Wuhan in 
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2019 indicated high conservation of RBD genetic sequence, compared with other genetic regions 
(Figure 4-6a,b), thus highlighting RBD as a promising target for COVID-19 vaccine development.  
We synthesized RBD-loaded NVP as described above. Loading of RBD in NVP was 
quantified by PAGE analysis, which showed ~21% loading efficiency (Figure 4-6c). The resulting 
RBD-loaded NVP (RBD-NVP) had a hydrodynamic size of ~240 nm as measured by DLS (Figure 
4-1b). Surface-display of RBD on RBD-NVP was examined by direct immunofluorescence as 
described. RBD-NVP was incubated with human RBD neutralizing antibodies, followed by 
washing and addition of AF488-labeled anti-human IgG secondary antibody. RBD-NVP exhibited 
a significantly higher fluorescence signal, compared with blank NVP control (Figure 4-6d), 
indicating the proper display of RBD and preservation of epitopes in RBD-NVP. 
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Figure 4-6. Genomic deviation of SARS-CoV-2 by coding region and characterization of RBD-NVP. (a) Spike protein is the 
most genetically conserved region within the genetic sequence of SARS-CoV-2, based on variants appearing with near 100% 
similarity to the original SARS-CoV-2 in this region. (b) RBD of SARS-CoV-2 variants has the highest sequence similarity to that 
of the original SASR-CoV-2 with the smallest deviation, compared with other domains. (c) RBD loading in NVP was confirmed 
by SDS-PAGE analysis. (d) RBD display on NVP surface was assessed by incubation with human anti-SARS-CoV-2 neutralizing 
antibody, followed by incubation with Alexa Fluor 488-labeled anti-human IgG1 Fc secondary antibody. Antibody bound to NVP 
was quantified by fluorometry. Data are presented as mean ± SEM. ***p < 0.001, ****p < 0.0001, analyzed by one-way ANOVA, 
followed by Tukey’s HSD multiple comparison post hoc test. 
 
RBD-NVP vaccination study in mice 
Lastly, we examined the potency of RBD-NVP to generate anti-RBD antibody response in 
mice. BALB/c mice were vaccinated three times with 2 weeks interval between each injection 
(days 0, 14, and 28) using 0.5 µg of RBD and 1 µg of MPLA either in NVP or soluble formulation 
(Figure 4-7a). Sera samples were collected on days 28, 42, and 70 and assessed for RBD-specific 
serum IgG, IgG1, and IgG2a titers. RBD-NVP generated significantly higher RBD-specific 
antibody titers, compared with RBD + MPLA soluble vaccine (Figure 4-7b-d). Specifically, by 
day 42 (2 weeks after 3rd vaccination), RBD-NVP elicited 55-fold, 17-fold, and 284-fold higher 
RBD-specific IgG, IgG1, and IgG2a titers, respectively, compared with the soluble vaccine (Figure 
4-7b-d). By day 70 (6 weeks after 3rd vaccination), mice immunized with RBD-NVP still 
maintained 30-fold, 13-fold, and 671-fold higher RBD-specific IgG, IgG1, and IgG2a titers, 
respectively, compared with the soluble vaccine group (Figure 4-7b-d). While the examination of 
functionality and neutralizing activities of these antibodies are beyond the scope of our current 
studies, these initial results indicated that RBD-NVP induced robust, long-lasting, Th1/Th2-
balanced antibody responses against RBD.  
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Figure 4-7. RBD-NVP elicits robust RBD-specific antibody responses in mice. (a) BALB/c mice were vaccinated three times, 
with 2 weeks intervals between each injection. Blood was sampled on the indicated days. RBD-NVP significantly increased serum 
antibody titers of RBD-specific (b) IgG, (c) IgG1, and (d) IgG2a, compared to the soluble vaccine. Data are presented as mean ± 
SEM. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001, analyzed by two-way ANOVA, followed by Tukey’s HSD multiple 
comparison post hoc test. 
 
4.5. Conclusion 
Overall, we have developed NVP for the delivery of protein antigens and demonstrated the 
versatility of NVP for protein-based vaccination against infectious pathogens. Protein antigens 
incorporated into NVP maintained the configuration of the epitopes, as shown by the recognition 
and binding of neutralizing antibodies on the surfaces of antigen-displaying NVP. NVP was 
readily taken up by DCs in vitro, leading to greater DC activation and antigen presentation, 
compared with soluble vaccine formulation. We have successfully prepared NVP carrying SOSIP 
derived from HIV-1 and RBD derived from SARS-CoV-2. Animals immunized with NVP 
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generated strong antigen-specific antibody responses. While these initial proof-of-concept studies 
have shown the promise of NVP, more studies are warranted to delineate the immunological 
mechanisms of action and to assess protective immunity against viral challenge (e.g., HIV-1 or 
SHIV challenge in non-human primates; and SARS-CoV-2 challenge in mice engineered to 
express human ACE2).   
  
 71 
CHAPTER V. Prebiotics Treatment for Modulation of Gut Microbiota and Improvement 
of Cancer Vaccine Efficacy 
 
5.1. Abstract 
It has long been known that diet has close relationship with the state of gut microbiota. Many 
dietary fibers are the sources for fermentation by the gut bacteria, which produce metabolites that 
have influence on the host in diverse aspects. Recent reports stating the close correlations between 
the gut microbiota and onset of diseases that were considered to be difficult-to-treat, such as cancer, 
autistic and autoimmune diseases, drew a lot of attention from various fields of study. Especially, 
the findings of bacterial metabolites called short chain fatty acids (SCFA) influencing the immune 
responses following therapeutic interventions sparked a huge interest in the field of cancer 
immunotherapy. Here, we sought to use engineering approaches to enhance the immune response 
after vaccination, by including prebiotics in the diet in an attempt to modulate the gut microbiota. 
Tested with mouse tumor models, several prebiotics such as potato starch and fructo-
oligosaccharide were found to induce changes in gut bacterial frequencies and subsequent immune 





The microbiome is a collection of genes from trillions of microorganisms living inside an 
individual human. Each organ inside the body has its own unique microbiota developed, all of 
which have been known to have great impact on general human health. Gut microbiota has been 
one of the most extensively studied among others. Since 2010, an avalanche of studies reported 
the relationship between the gut microbiota and health and disease onset of other organs of the 
body (163). Especially, there are many recent studies reporting close relationships between the 
host gut microbiota and the immune system, where both members of the innate and adaptive 
immunity are found to be strongly influenced. Consumption of dietary fibers diversifies bacteria 
in the gut, which subsequently influences various members of the immune system, including 
dendritic cells, macrophages, regulatory T cells and memory T cells (55, 164, 165). Also, there are 
accumulating reports of certain bacterial species and their metabolites modulating patients’ 
responses to immunotherapies (166, 167).  
For the communication between microbiota and immune system, the metabolites of 
bacteria called short chain fatty acids (SCFA) act as one of the crucial mediators (55, 164). When 
bacteria metabolize, the metabolites called short chain fatty acids (SCFA) are released, which act 
as a mediator for the cross-talk between the gut microbiota and the immune system, ultimately 
contributing to therapeutic outcomes during cancer immunotherapy (168, 169). In the similar 
context, consuming dietary fibers, or prebiotics, which bacteria metabolize on has also been found 
to be important for the general health and immunity of an individual. With recent findings of SCFA 
acting as an important factor for the generation and potency of memory T cells, there are increasing 
interests in the field of immunology to investigate the effects of microbiota and T cell immune 
responses (165). However, despite the reports suggesting potential connections between the diet, 
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microbiota and immune responses (166, 167), there have not yet been studies of how the diet 
influences T cell responses after vaccination in cancer prophylactic/therapeutic settings. Here, we 
investigated the effects of prebiotics consumption on microbiota and how the changes in 
microbiota influence the T cell response generated by vaccination against cancer using a mouse 
tumor model. There are many prebiotics known to have effects on gut microbiome when consumed, 
such as inulin (170, 171), metformin (172-174), pectin (175, 176) and potato starch (177). Prior to 
tumor inoculation, these prebiotics were given by oral gavage followed by vaccination. Many of 
the prebiotics that were tested were shown to have influence on bacterial composition in the gut, 
including the increase in Akkermansia frequency, which has been found to be closely related to 
host’s immune response during cancer immunotherapy (168). 
 
5.3. Materials and Methods 
Animal studies 
Animals were cared for following federal, state, and local guidelines. All experiments 
performed on animals were in accordance with and approved by the Institutional Animal Care and 
Use Committee (IACUC) at the University of Michigan, Ann Arbor. BALB/c mice (n=5 per group) 
were given oral gavages with prebiotics using below indicated amounts: 
 Experiment #1 Experiment #2 
Vaccination: 
Adpgk HDL 
(15.5 nmol + 2.3 
nmol CpG); 
injected s.c. at 
tail-base 




Inulin gel 60 mg 
Metformin 6 mg FOS 150 mg 
Pectin 10 mg Potato starch gel 30 mg 







No vaccination Water NA Water NA 
*Indicated doses are amount per gavage given to each mouse. 
Oral gavages were given using 22-gauge gavage needles (Cadence Science™) once every 2 days 
for 47 days (experiment #1) or for 8 days (experiment #2). Each gavage volume was fixed to 100 
µl. Vaccinations were given subcutaneously at the tail-base, injected on both sides with 50 µl 
injection volume per side. For serum IgG detection study, OVA (100 µg) and Alum (Alhydrogel, 
Fisher Scientific, 50% of total injection volume) (instead of the adpgk-HDL formulation) were 
given as vaccination. Fecal samples were collected at indicated time points using 1.5 mL 
centrifugal tubes, placed in dry ice immediately after collection. Blood samples were collected via 
submandibular vein using lancets. Collected blood samples were used for analyses using flow 
cytometry and ELISA. 
ELISA for serum IgG titer measurement 
Mouse immune sera were analyzed for adpgk-specific IgG antibody titers using ELISA. 
Briefly, ovalbumin was coated on 96-well ELISA plates (1 µg/well) and serially diluted sera 
samples were added. After 1 hr of incubation and multiple washings, horse radish peroxidase 
(HRP)-labeled secondary antibodies were added and further incubated for 1 hr in room temperature. 
Rabbit anti-mouse IgG H&L-HRP (Abcam) was used as the secondary antibody. Next, TMB 
substrate solution (Thermo Scientific) was added, and the reaction was stopped by the addition of 
H2SO4. The absorbance was measured at a 450 nm wavelength using a plate reader (Synergy Neo, 
BioTek). To measure antibody titers, titration curves were drawn based on the absorbance and the 
dilution factor, from which half maximal effective concentration (EC50) values were calculated 
using Prism 7 software. 
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Flow cytometry for analysis of antigen-specific CD8+ T cells in blood 
Red blood cells in the collected blood samples were removed by mixing with ACK lysis 
buffer (Life Technologies). After centrifugation at 500 g for 5 min, pallet was washed with PBS 
twice. Resulting PBMCs were stained with a live/dead staining dye (eBioscience), followed by 
mixing with Fc-receptor blocking antibody (anti CD16/32) and fluorophore-labeled antibodies 
including CD3-FITC (Biolegend), CD8-APC (BD Biosciences), and Adpgk tetramer-PE (NIH 
Tetramer Core Facility). Resulting cells were fixed with 2% formaldehyde for 10 min, and then 
suspended in FACS buffer for flow cytometry. 
Statistical analysis 
The results are expressed as means ± SEM. Prism 7.0e (GraphPad Software) software was 
used for statistical analyses. Statistical comparisons were performed using one-way or two-way 
ANOVA, followed by Tukey's HSD multiple comparison test or Sidak’s multiple comparison test, 
as indicated. The survival curves were analyzed by the log-rank (Mantel−Cox) test. Statistical 




 Effects of prebiotics on CD8+ T cell responses after vaccination were examined using 
BALB/c mice (n=5 per group). Mice were acclimated for a week to stabilize gut microbiota. Oral 
gavages with prebiotics were given bi-daily using gavage needles with each gavage volume of 100 
µl. Doses of prebiotics are indicated in the methods section. 7 days into the gavage period, mice 
were vaccinated subcutaneously at the tail-base with HDL nanodiscs containing CpG (2.3 nmol) 
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and adpgk peptide (15.5 nmol). Booster injections were given twice with 2 weeks intervals. MC38 
tumor cells were injected on day 47 which was the last day of prebiotics treatment. Blood samples 
were collected on days 14, 28, 40 and 54 for flow cytometric analyses on peripheral CD8+ T cells. 
Fecal samples were collected on day 7 (Figure 5-1a). Using blood samples, adpgk-tetramer 
staining analysis was performed on CD8+ T cells (Figure 5-1b). All treatment groups including 
water-treated group that was not given prebiotics showed increase in peripheral frequency of 
antigen-specific CD8+ T cells over time. Although statistically significant difference between 
water-treated and any of the prebiotics-treated groups was not observed, there were trends of shifts 
in adpgk-specific CD8+ T cell levels that fluctuated over time. Mostly, the water-treated group 
showed the trend of lowest frequency, indicating that it is likely that prebiotics treatment has an 
impact on CD8+ T cell responses after vaccination. Similarly, effector and memory T cell 
formation showed trends of variances depending on prebiotics treatment, albeit without statistical 
significance (Figure 5-1c). Serum IgG levels were measured using ELISA (Figure 5-2d). Again, 
trends of variance between treatment groups were observed without statistical significance, where 
we were able to assume that prebiotics treatment indeed has influence on immune responses 
including CD8+ T cell and serum antibody.  
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Figure 5-1. Effects of prebiotics on cellular and humoral immune responses induced by vaccination. (a) Schematic of 
experiment timeline. Mice (n=5 per group) were given three times of vaccination (prime and two boosters) on days 7, 21 and 33, 
while they were given oral gavages of prebiotics every two days for 47 days. Fecal samples were collected on day 7 and blood 
samples were collected on days 14, 28, 40 and 54. (b) adpgk-tetramer staining using blood samples collected on indicated dates, 
analyzed with flow cytometry. (c) Analysis of effector and memory cell transition by peripheral CD8+ T cells over time, measured 
by flow cytometry. (d) Serum IgG levels indicated in EC50 of reciprocal serum dilution, measured by ELISA. 
 
In order to investigate how prebiotics have influenced the immune responses, fecal samples 
were analyzed to investigate the microbiome using 16S RNA sequencing. Among 125 bacterial 
species analyzed, noticeable shifts were observed from several species including Alistipes, 
Akkermansia, Lachnospiraceae, Bacteroides and Turicibacter (Figure 5-2a). Interestingly, 
 78 
Akkermansia, which is reported to be beneficial for colonic mucin and overall gut health (178-
180), showed trends of increase in metformin- and pectin-treated groups. In order to investigate if 
the impact on gut microbiota by prebiotics treatment has influence on anti-tumor vaccine efficacy, 
the mice that were given prebiotics and vaccinations were challenged with subcutaneous injections 
of MC38 mouse colon carcinoma cells on day 47, and the tumor growths were monitored (Figure 
5-2b). Interestingly, tumor growth suppression had trends of enhancement when prebiotics were 
given together with vaccination to tumor-bearing mice. FOS, metformin and inulin were shown to 
have significant enhancement compared to other prebiotics. Although a noticeable survival 
benefits were not observed (Figure 5-2c), the results indicate that prebiotics treatment have 
impacts on gut microbiome which subsequently influences on host’s immune responses after 
prophylactic vaccination against tumor. 
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Figure 5-2. Changes in gut microbiome and their effects on vaccine efficacy in tumor-bearing mice. (a) Several gut bacterial 
species with trends of deviance compared to water-treated group are shown. Tumor growth curve (b) and survival (c) of tumor-
bearing mice that were given oral gavages of any one of water, inulin, FOS, pectin, metformin or fucoidan in combination with 
vaccination. Control group was given oral gavages of water without vaccination. For statistical analysis shown in (b), the top panel 
compares between ‘water’ and ‘FOS’, and the bottom panel compares between ‘water’ and ‘metformin’. Data are presented as 
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, analyzed by two-way ANOVA followed by Sidak’s 
multiple comparisons test. 
 
Next, a similar animal study was designed, this time with a therapeutic setting. Oral gavage 
period was given for 8 days, which was shortened compared to the previous gavage period of 47 
days, based on a study reporting rapid change of microbiota of mice that occurs around 7 days 
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after cohousing in a different environment (181). These mice were inoculated subcutaneously on 
the right-side thigh on day 0 with MC38 cells. 4 days later, mice were given primary vaccination 
with adpgk-CpG-HDL (15.5 nmol adpgk + 2.3 nmol CpG). Two booster injections with the same 
dose, each given weekly. Fecal samples were collected on day 6 for microbiome analysis. Blood 
samples were collected on days 11, 18, 25 and 32 for adpgk-tetramer analysis on peripheral CD8+ 
T cells (Figure 5-3a). Similar to the previous experiment, trends of increase in antigen-specific 
CD8+ T cells were observed in peripheral blood until day 18, but not on day 25 and after (Figure 
5-3b). It may have been due to the long period of time since the cessation of oral gavages of 




Figure 5-3. Effects of prebiotics on therapeutic efficacy of vaccination against tumor. (a) Timeline of study. BALB/c mice 
(n=7) were given prebiotics every two days for 8 days, followed by tumor injection using MC38 mouse colon carcinoma cells. 4 
days after, mice were given vaccination once every week for three times. Fecal samples were collected on day 6, and blood samples 
were collected on days 11, 18, 25 and 32. (b) adpgk-tetramer staining on CD8+ T cells in peripheral blood, measured by flow 
cytometry. (c) 16S RNA sequencing data of fecal samples. Bacterial species that showed most noticeable changes are shown. (d) 
Tumor growth and (e) survival of tumor-bearing mice that received with or without vaccination and prebiotics treatment. For 
statistical analysis shown in (d), left panel compares between ‘water’ and ‘potato starch gel’. Data are presented as mean ± SEM. 
*p < 0.05, **p < 0.01, and ****p < 0.0001, analyzed by c) one-way ANOVA followed by Tukey’s HSD multiple comparison post 
hoc test or d) two-way ANOVA followed by Sidak’s multiple comparisons test. e) The survival curves were analyzed by the log-
rank (Mantel−Cox) test. 
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Fecal samples were analyzed with 16S RNA sequencing to investigate the changes in gut 
bacterial frequencies (Figure 5-3c). There were noticeable changes in several species of bacteria, 
including Akkermansia, Faecalibaculum and Coriobacteriaceae, depending on the prebiotics 
given. Interestingly, changes in Akkermansia were again observed as was in the previous study, 
indicating the potential positive effects of the tested prebiotics on the gut health. In line with the 
tetramer-staining study and changes observed in gut microbiome, mice given prebiotics showed 
trends of enhanced vaccine efficacy against tumor, correlating with increased survival of the 
tumor-bearing mice (Figure 5-3d,e).  
 
5.5. Conclusion 
Overall, we were able to observe the effects of prebiotics on vaccination efficacy against 
tumor, by the trends of changes in gut microbiome and in both cellular and humoral immune 
responses. Most importantly, despite the changes showing only the trends of changes that require 
multiple rounds of additional experiments to confirm reproducibility of the results with statistical 
significance, the efficacies of vaccines both in prophylactic and therapeutic settings showed 
enhancement when the tested animals were given oral gavages of certain prebiotics (e.g., potato 
starch, FOS, etc.). It states the possibility of diet-based preconditioning being included in the 
cancer therapeutic regimens and the importance of healthy diet that includes dietary fibers to 
maintain gut microbiota in a state that is beneficial for the prevention of neoplasm. Also, the study 
warrants further studies to investigate the effects of bacterial metabolites that are produced within 
the microbiota that is changed after prebiotics consumption. 
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CHAPTER VI. Conclusions and Perspectives 
 
There is an overarching aim that is shared between the studies described thus far, which is 
modulating the immune response to achieve enhancement of therapeutics or prophylaxis. Immune 
responses can be perceived as a cycle that begins with recognition of antigen and danger signals 
by innate immune response that leads to activation of adaptive immune response, where 
modulation at a certain stage may bolster the cycle, leading to stronger overall immune responses. 
Our studies used biomaterials to target a certain stage of immune response cycle that depended on 
the type of material used, kind of therapeutic or prophylaxis, administration route and target 
disease. 
In the first study, bMSN-mediated STING agonist delivery increased cellular uptake of 
STING agonist that enhanced STING activation of dendritic cells, subsequently leading to 
improved therapeutic outcomes of STING agonist treatment in mouse melanoma models. Here, 
we expect the large-sized pores of bMSN will not only enable the fast degradation of bMSN after 
administration, but also provide a possibility for larger-sized biomolecules, such as protein, to be 
loaded in bMSN which would make the system applicable to other therapeutic settings. Also, 
utilizing well-known silica surface modification chemistries may allow multiple kinds of 
biomolecules to be co-loaded, further diversifying the application scenarios. Meanwhile, the 
current study was done using mouse melanoma model, where the tumor was easily accessible for 
direct injections of bMSN loaded CDA, after which the presumed acidic tumor microenvironment  
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allows prolonged CDA release. However, there are many situations where tumors are not readily 
accessible for direct injections, in which case, other routes of drug administration should be 
considered. Intravenous injection is one of the commonly used routes of injection, where passive 
drainage of drug or delivery particles occurs to the sites of tumor via enhanced permeability and 
retention (EPR) effect (182, 183). In this case, the administered therapeutics are exposed to and 
interact with components, including albumins, present in the blood circulation, causing clearance 
at different parts of the body such as liver and kidney (184). It would be a great direction to pursue 
forward to modify the surface of bMSN, such as lipid- or polyethylene glycol-coating, to increase 
stability in blood circulation which would provide other possible routes of administration. 
The next study introduced combination of nanoparticle vaccine and STING agonist for 
cancer immunotherapy. The nanoparticle vaccine was used to enhance the potency of a neoantigen 
peptide vaccine, while STING agonist treatment induced stronger release of T cell attractant 
chemokines from tumors, leading to increased tumor infiltration by the vaccine-induced T cells. 
The combination treatment was strategically designed to overcome suboptimal tumor infiltration 
by T cells, a limitation frequently faced by vaccines designed for cancer immunotherapy. Causes 
that lead to such limitation and were attempted to be solved in the study include sequestration of 
T cells at the vaccine depot which is often formed when certain types of vaccine delivery platforms 
are used, and minimal expression of chemokines by the tumor (185-187). Importantly, the concept 
of recruiting circulating T cells to tumor may be applicable in different settings such as when T 
cells are adoptively transferred, which also increases the available number of T cells in the blood 
circulation (188). However, while STING agonist has worked out nicely in the current study, 
sensitivity to STING agonist treatment varies by the tumor types where excessive dose of treatment 
may cause suboptimal immune responses (71), requiring dose optimizations. Therefore, it would 
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also be worthwhile to test other types of drugs that may substitute STING agonist to achieve similar 
effects for flexibility of adopting the idea of T cell recruitment in other therapeutic settings 
involving different types of tumor. For example, there are studies investigating the recruitment of 
circulating T cells to tumor, adopting the concept of vascular checkpoints where extravasation of 
T cells is controlled using various agents, such as cisplatin, temozolomide, or other anti-angiogenic 
agents (105, 188-190). 
Next discussed was lipid-based nanoparticle mediated protein subunit vaccine delivery as 
prophylaxis against infectious diseases, where the vaccine was codelivered with an adjuvant, 
MPLA, to enhance activation and antigen presentation by dendritic cells, which together with 
increased lymph node trafficking after subcutaneous administration induced stronger humoral 
immune responses in mice and rabbits. Another emphasis put in the study was maintaining the 
tertiary and quaternary structures of the protein antigens during the loading process into 
nanoparticles, since it is critical to the generation of neutralizing antibodies that are able to 
neutralize the pathogens after vaccination (191). The study involved various ways to examine the 
conformational intactness of the protein antigens after incorporation into the nanoparticle, such as 
non-reduced SDS-PAGE, native blue PAGE, and neutralizing antibody treatment followed by flow 
cytometric analysis. From the previous generations of the lipid nanoparticles with similar 
multilamellar lipid structures (152-154), the current version excluded the use of excessive physical 
stress and reducing agents after protein antigens were added to the reaction mixture, in order to 
prevent the structural disruptions that may occur. As a result, two different kinds of proteins, each 
having internal disulfide bonding and/or trimeric structure, were successfully loaded in the 
nanoparticle with great loading efficiencies (20~25%), demonstrating the applicability of the 
system to delivering various proteins with different structural characteristics. However, while the 
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generation of IgG antibodies in serum of vaccinated mice and rabbits have been confirmed, further 
studies are warranted for the validation of IgG-mediated neutralization of pathogens both in vitro 
and in vivo settings. 
Lastly, the effects of prebiotics consumption on gut microbial composition and subsequent 
immune response after vaccination was investigated using a mouse tumor model. Many studies 
reporting the correlations between the gut microbiota and various immune cell types provided the 
motivation to this project. Here, controlling the diet through consumption of prebiotics was 
proposed as a means for modulating the immune responses based on the links between prebiotics 
consumption, gut microbiota, and the immune system. Using mouse models, changes in gut 
bacterial composition upon oral delivery of prebiotics, including inulin, potato starch, fructo-
oligosaccharide and metformin, were observed. Together with the impact given to gut microbiota, 
we observed trends of enhancements in cellular and humoral immune responses upon vaccination, 
which correlated with improved the potency of vaccines treated in either prophylactic or 
therapeutic settings. Overall, the study provided a promising strategy for immune modulation that 
provides possibility of applying to other therapeutic settings. However, the duration of oral gavage 
adopted in the two studies were either relatively short or the gavage was seized after tumor 
challenge, from which point the gut microbiota may normalize back to the initial state. Therefore, 
it warrants additional studies of how prolonging the duration of prebiotics treatment may influence 
the microbiota and the immune responses. Also, the bacterial metabolites, SCFA, are in part 
responsible for the effects the bacterial community provides to the immune cells, and therefore 
should also investigated in detail in future studies (53, 55, 58, 192). 
Overall, here in the thesis, various ways of immune modulation for treating cancer and 
preventing infectious diseases were introduced. While some of the studies were more directed 
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towards proof-of-concept, others were focusing on the clinical translatability. Altogether, the 
future direction to which all our studies should be pursuing onward is getting thorough mechanistic 
insights in terms of how the immune system reacts to the therapeutic/prophylactic inputs given by 
our systems, such as nanoparticle mediated vaccine and drug delivery, intratumoral STING agonist 
treatment, and prebiotics treatment.  Tracking the drug or delivery particles after administration in 
longer terms, analyzing the immune response bias to Th1 or Th2 responses, and investigating other 
cell types that are also important during immune responses, such as macrophages and B cells, 
would provide clearer vision of how the therapeutic outcomes can be expected in clinical settings. 
With these clearly defined, our systems may provide great bases for combination therapies with 
other potent immunotherapeutics, such as immune checkpoint inhibitors and adoptive cell transfer 
of T cells and DCs. With currently available immunotherapies, still a large portion of patients fails 
to achieve complete responses (193, 194). Our studies may provide alternative therapeutic methods 
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